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Abstract 
Synthesis, Characterization and Biological Studies of 99mTc and 188Re Peptides 
Vanessa Sanders 
Advisors: Ken Czerwinski and Lynn Francesconi 
Radiopharmaceuticals are very powerful diagnostic tools for evaluation of a host of 
medical conditions.  These drugs are labeled with radioactive isotopes, which are utilized to 
create pictures of areas of interest through absorption of the drug. They are currently in high 
demand due to their ability to image areas that traditional imaging devices cannot. The 
radioisotope 99mTc, with a half-life of 6.01 hours and a 140 keV gamma emission, is central to 
many radiopharmaceutical compounds. This isotope is easily obtained from a 99Mo-99mTc 
generator, through beta decay and column chromatography separations. Very little technetium, 
less than 6 ng, is needed to label the pharmaceuticals for use in-vivo.  Another radioisotope 
188Re is also important due to its ability to be used for therapy while being tracked throughout 
the body. Radiotherapy gives radiopharmaceuticals a huge advantage by their ability to destroy 
rapidly growing cells. One of the main reasons there is interest in rhenium pharmaceuticals is 
the chemical similarity between it and technetium. The 188Re isotope also has a considerably 
short half–life of approximately 17 hours and has emission energy of 155 keV. The 188Re isotope 
is separated from 188W-188Re generator, analogously to the 99Mo-99mTc generator.  
The ligand used in this work is a pentapepetide macrocyclic ligand. This ligand, KYCAR 
(lysyl-tyrosyl-cystyl-alanyl-arginine), has been designed as a potential chelating ligand for 
 
iv 
 
imaging and therapeutic in vivo agents. Ligands are chosen based on their in-situ biological 
behavior, and are used in the complexation with technetium and rhenium. Understanding and 
exploiting technetium and rhenium chemistry can provide insight into the reaction mechanisms 
and coordination chemistry of these compounds. The exploration of various oxidation states as 
a function of the ligands used and the reaction conditions can help develop novel 
radiopharmaceuticals. The investigations of the manipulation of oxidation states have the 
possible application to simplify the synthesis of the pharmaceutical. The versatility of the 
oxidation states of these metals leads to numerous possibilities in developing new 
radiopharmaceuticals.   
 The coordination chemistry and reaction mechanisms must be efficiently characterized 
to ensure the reproducibility of the radiopharmaceutical. The current study focuses on 
technetium and rhenium complexes with peptides. These complexes have become increasing 
interesting for their use in diagnostic and therapeutic radiopharmaceuticals. The 
characterization of the complexation of Tc(V), and Rh(V) with the pentapeptide KYCAR (lysyl-
tyrosyl-cystyl-alanyl-arginine) will be discussed. Complexes will be characterized by High 
Performance Liquid Chromatography (HPLC), UV-Visible Spectroscopy, Proton NMR, Circular 
Dichroism (CD), and Electrospray Ionization Mass Spectroscopy, to compare them to current 
radiopharmaceuticals.  Information on the underlying reactions and coordination will be 
discussed. 
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1. Introduction 
1.1. Background 
Radiopharmaceuticals are very powerful diagnostic or therapeutic tools for evaluation 
of a host of medical conditions, which include defect in organs, infection and most notably 
cancer. In 2014 over 14 million people reported having a history of cancer and nearly 2 
million people would be diagnosed within the next few years. 1 As the amount of people 
diagnosed and the need for earlier detection increases the demand for optimal 
radiopharmaceuticals also increases.  
By definition radiopharmaceuticals are drugs, organic or bioorganic molecules, that 
include a radionuclide. The radionuclides, depending on the isotope emit particles and can 
be utilized to create pictures or induce therapy on areas of interest through absorption of 
the drug. 2, 3 Before a radionuclide can be incorporated into a drug it first must possess 
certain properties for radioimaging or radiotherapy. Depending on the application must 
emit ionizing particles, alpha (α), beta (β), or gamma (γ). Specifically, for radioimaging the 
particles must emit penetrating radiation which consists of gamma rays, either direct or 
through positron emission. The energies of the gamma rays are dependent on the nature of 
the gamma particle and are used with specific detection instruments. For instance, gamma 
particles that are the product of the annihilation of positron are 511 keV and are released at 
approximately 180° from each other. Nuclides that emit positron particles, and the resulting 
511 keV photons, are exclusively used in Positron Emission Tomography (PET). Nuclides that 
 
2 
 
emit incident gamma rays are typically used with Single Photon Emission Computed 
Tomography if their energies are within the range of 100- 250 keV.  
Next, the nuclide of interest must have a half-life, the time in which half the particles 
have decayed, that is of an adequate length. An effective half-life is one where there is 
sufficient activity to image the area of interest post synthesis, purification, and injection. In 
order to reduce dose to the patient the nuclide should also decay to a stable daughter or to 
a nuclide with a relatively short biological half-life.  
Finally, the cost and availability to produce the nuclide of interest plays an important 
role. Most nuclides are produced by cyclotrons, accelerators, or through a generator 
system. Accelerators/ cyclotron production systems have the potential to produce multiple 
isotopes at a single location. This increases the application, allowing for detailed exploration 
through the utilization of multiple isotopes. However, production utilizing this system can 
be expensive and limits availability to areas outside of the production facility. Alternatively, 
a generator system, where a parent or longer-lived nuclide is adsorbed onto a 
chromatographic column and as it decays the shorter-lived nuclide of interest is eluted for 
use. This production system is more cost effective and since the generator can be shipped 
the nuclides of interest become more available. An isotope can possess excellent energies 
and optimal half-lives, however if it is impractical to produce it will not be a good candidate 
for a radiopharmaceutical.  
Some of the first radionuclides produced for medical commercial use were 24Na, 32P, and 
most notably 131I. Phosphorus and sodium were used during that time to analyze cardiac 
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functions.4, 5  Iodine is currently being used for imaging and therapy after uptake in the 
thyroid was noticed as early as 1938.6, 7 One of the first myocardial scintigraphy 
radiopharmaceuticals used, that is still used today, was 201Tl, and was discovered by Strauss 
et al. in 1975. 8 Many nuclear medicine scans are used for the detection of bone 
metastases. Bone scintigraphy began in the 1960’s using 85Sr as the radionuclide. Many of 
these early radionuclides have been replaced with 99mTc, presently the most widely used 
diagnostic radioisotope. Table 1 shows some of the commonly used radionuclides for 
radiopharmaceuticals. 
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Commonly Used Radionuclides 
Radionuclide  Half-life Most Common 
Production Methods 
Particle 
Emission 
Application 
11C 20.3 m Cyclotron β+ PET 
18F 109.7 m Cyclotron β+ PET 
67Ga 78 h Cyclotron EC SPECT 
68Ga 68 m Generator β+ PET 
111In 2.80 d Cyclotron EC SPECT 
99mTc 6.01 h Generator IT SPECT 
131I 8.02 d Reactor β- Therapy 
82Rb 1.27 m Generator β+ PET 
201Tl 3.05 d Generator EC SPECT 
123I 13.2 h Cyclotron EC SPECT 
89Zr 78.4 h Accelerator/Cyclotron β+ PET 
90Y 64.1 h Reactor β- Therapy 
64Cu 12.7 h Accelerator β+ PET 
Table 1. List of Commonly Used Radionuclides for Radiopharmaceuticals 
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1.2.  PET/ SPECT Instrumentation 
Early detection of diagnostic radiopharmaceuticals utilized basic gamma cameras for 
planar imaging. In this practice as the emitted gamma was being detected, a lead collimator 
was used to guarantee that the path of the particles being collected parallel to one another. 
From there the particles were transformed from photons to visible light using a scintillator and 
the particles are amplified through photomultiplier tubes. Finally, the origin of the incident is 
determined from various electronics and a 2D picture is created. While this was a novel 
technique, one major trepidation was the attenuation of the emitted particle by other organs. 
Also, the lack of sensitivity within the detector results in poor resolution of the final image. As a 
result, currently there are two main modalities used for the detection of incident particles and 
tomographic reconstruction.  
  Positron Emission Tomography (PET) imaging employs the use of radionuclides that emit 
positrons. Most commonly the isotope 18F and the compound fluorodeoxyglucose are used in 
the PET imaging to measure tissue metabolism. These positrons are subsequently annihilated 
upon interaction with an electron producing two 511 keV photons (Figure 1).9 The photons are 
emitted approximately 180° from each other which enhances the reconstruction of the location 
of the incident event. The detectors are configured as a circular ring of block detectors coupled 
to photo multiplier tubes. The scintillation crystals, which convert the photons to visible light, 
are used to achieve more incidences thus allowing for better spatial resolution. When both 
photons are detected simultaneously within the timing window of about 10 ns a line of 
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response is created. Through additional electronics and the summation of the created line of 
response an image is formed.10, 11 The main advantage for PET imaging is better resolution of 
the images than found in SPECT imaging. This does not negate the fact that the instrumentation 
has room for improvement. The performance of the instrument can be enhanced by the 
optimizing the scintillation crystals, photo multiplier tubes and the geometry and location of 
the detectors.12  
 
 
Figure 1. Positron emission and annihilation 
 
 
 Single Photon Emission Computed Tomography (SPECT) imaging evolved from the first 
planar detector used in nuclear medicine. Typically, nuclides used with SPECT imaging are those 
that emit gamma particle with energies ranging between 100-250 keV. The most common 
radionuclide that utilizes this application is 99mTc. These gamma rays are produced through one 
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of two mechanisms: the photoelectric effect or Compton scattering. In the photoelectric effect, 
an incident photon displaces an inner electron from its shell, as it deexcites a photon is emitted. 
Conversely in Compton scattering an incident photon is deflected resulting from its interaction 
with an inner electron (Figure 2).13 The major disadvantage to SPECT imaging is the poor 
resolution compared to PET, attributed to many factors with the detector system as well as 
keeping the dose low to the patient. Collimators play an important role in the detection of 
gamma particles and assist in determining the location of the incident event. This is due to the 
collimator only recording events from a specific position and direction, eliminating all other 
gamma particles. In early SPECT designs the detector used is often noted as the Anger camera 
14, 15, consisting of a collimator, scintillation crystal, and photon multiplier tubes.16 Since the 
primary goal is a local image of the area of interest optimization of the detection system is of 
upmost importance. To suppress photons that may have scattered upon exiting tissue only 
photons of a specific energy are recorded. Also, multiple scintillation crystals were introduced 
to increase the probability of interaction with the photon. Another approach is replacing the 
crystal, typically NaI(Tl), with solid state detectors. As further research on improving the 
components of the detector system is completed the overall resolution will improve. Currently, 
to circumvent resolution issues SPECT systems are coupled with computed tomography (CT) 
systems to improve the quality of the images.17   
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Figure 2. Photoelectric effect and Compton scattering 
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1.3.  Technetium Chemistry and 99mTc Radiopharmaceuticals 
 Technetium, the most widely used medical isotope, is a transition metal which sits in the 
middle of the periodic table (Figure 3). The lightest synthetic element was discovered in 1937 
by Pierre and Segre through a cyclotron irradiation of molybdenum foil. 18 
 
 
 
Figure 3. Periodic Table of Elements 
 
 
It is the lightest synthetic elements with an atomic number of 43 and over 30 isotopes. The 
most common isotope of technetium is 99Tc, which has a half-life of 210000 years is produced 
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as a fission product of uranium ion nuclear reactors (Figure 4). The A=99 isobar have a 
cumulative fission yield of 6.1% from the fission of 235U by thermal neutrons.19 While the 
independent fission yield of 99mTc is relatively low, the isobaric beta decay produces the isotope 
through 99Mo with a half-life of 2.747 days. The stable end member of the A=99 fission product 
isobar is 99Ru. 
 
 
 
 Figure 4. Decay chain of Tc from fission products  
 
 
 The isotope 99Tc is separated from the other fission products through various 
reprocessing techniques, such as liquid-liquid extraction via the uranium extraction (UREX) 
process. Trace amounts of technetium can also be found in the earth’s crust, as 98Tc, and in red 
giant stars.20 Despite being the lightest artificial element technetium has a vast interesting 
chemistry with oxidation states ranging from -1 to +7. Technetium can form chemical bonds 
consisting of pi electrons and sigma electrons, that can be of colligative and coordinative types 
when spin compensation and electron pair donation occurs.21 Compounds have been reported 
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with coordination chemistries from 4 to 9 which allows for complexation to a wide range of 
ligands.   
 The isotope 99mTc is central to many radiopharmaceutical compounds and is used in 
over 85% of nuclear diagnostic tests, with over 25 million completed procedures each year.22 It 
has excellent physical properties (half-life= 6.02 hrs, gamma emission= 142 keV) and has 
optimal medicinal characteristics. Less than 6 ng is needed to label the pharmaceuticals for use 
in vivo. Also, the low γ ray energy allows for optimal imaging with current gamma camera 
technology, and its short half-life insures that the radiopharmaceutical can be injected with 
minimal radiation burden to the patient.23, 24 
 The production of 99mTc is facile and can be available to medical centers through the use 
of the 99Mo/99mTc generator, discovered by Brookhaven National Laboratory,25 with a shelf life 
of one week. Briefly the parent isotope, 99Mo (half-life= 66 hrs) as MoO4
2- is adsorbed onto an 
alumina column. As 99Mo continuously decays 99mTcO4
- is separated using saline, owing to the 
charge difference (Figure 5). Following the elution, the peak activity of 99mTc accumulates on 
the alumina column within 24 hours. However, if necessary the generator can be eluted earlier 
producing about half of the activity within 8 hours.26 
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Figure 5. Decay Scheme of 
99
MoO4
2-
 to 
99m
TcO4
-
 : The Chemistry of the Tc Generator 
 
 
 Once eluted Na99mTcO4
 is the conventional starting material for the majority of 99mTc 
radiopharmaceuticals. Generally, the eluate is introduced to a ‘kit’ containing a reducing agent, 
the ligand of choice and buffers. These instant kits were developed in the 1970 shortly after the 
development of several Tc imaging agents. The entire kit is then incubated at an elevated 
temperature and followed by purification before use. The development of the instant kits 
propelled the advancement of Tc radiopharmaceutical discovery, and by the late 1970’s 99mTc 
brain heart and renal imaging agents had been discovered.27  
 The first group of explored 99mTc imaging agents is tagged as “Tc essential” 
radiopharmaceuticals. These are the simplest and oldest agents with respect to 
radiopharmaceutical structure. These are non-targeted complexes that showed uptake in areas 
of interest due to the size, charge and lipophilicity of the complex. Examples include 99mTc-
DTPA, and 99mTc-DMSA, for the imaging of renal function. The second generation of imaging 
agents consisted of complexes where the design and structure was deliberate, characterized 
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and understood. Several brain and kidney 99mTc agents, for example 99mTc-HMPAO and 99mTc-
Mag3, are included in this generation. 
  The next wave of Tc imaging agents came around the late 1980’s, and involved Tc-
complexes bound to a biologically active molecule through the use of a linker molecule. Figure 
6 shows a depiction of a “tagged radiopharmaceutical”. Here Tc is complexed to a ligand; the 
resulting molecule has an available linker portion that can be used to conjugate to a targeting 
vector, usually a biologically active molecule (BAM). 
 
 
 
Figure 6. Tagged Radiopharmaceuticals 
 
 
 In this class of Tc radiopharmaceuticals, the targeting vector determines the distribution 
of the agent in the body by utilizing antibody/ antigens, or molecular targeted receptors. The 
99mTc apcitide (99mTcO(P246)) was the first radiolabeled peptide used in nuclear medicine. 
Complexation of Tc with the 13 amino acid shows high affinity and selectivity for the GPIIb/IIa 
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receptors. This agent has been successfully incorporated into a lyophilized kit with the trade 
name AcuTectTM, and used to image deep vein thrombosis.28-30 
  Pertechnetate, 99mTcO4
-, has an oxidation state of +7. However, many 99mTc 
radiopharmaceuticals require an oxidation state of +5 for complexation to ligands. When 
pertechentate is reduced, typically by a stannous ion, a technetium(V)-oxo core is formed. This 
technetium core describes a group of stable structures by which ligands can coordinate (Figure 
7).27 The Tc-oxo, Tc=O3+, core is most often used in conjugation with radiopharmaceuticals, 
typically N3S, or N2S2 tetradentate ligands. Upon formation with these ligands the geometry 
becomes square pyramidal with the Tc-oxo core in the apical position. The mechanism 
associated with N3S or similar ligand is a very strong bond between Tc
V and the thiolate 
followed by a deprotonation of the amide nitrogens resulting in a tetradentate complexation. 
When chiral centers are present in the ligand it is typical that diasteromers form, where side 
chains within the ligand are syn or anti to the Tc=oxo group. Tc radiopharmaceuticals have been 
used to image a vast array of areas within the body. The most notable are tabulated in the table 
below (Table 2). 
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Figure 7. Examples of Technetium Cores 
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Agent Commercial Name Oxidation State Area of Interest 
99mTc-MIBI CardioLite I Heart 
99mTc-BATO Cadiotec III Heart 
99mTc-Furifosmin TechneScan Q12 III Heart 
99mTc-Methyl 
Diphosphonate 
99mTc-MDP IV Bone 
99mTc-Tertrofosmin Myoview V Heart 
99mTc-HMPAO Certec V Brain 
99mTc-ECD Neurolite V Brain 
99mTc-Mag3 Technescan V Kidneys 
99mTc-Apcitide AcuTect V Deep Vein 
Thrombosis 
99mTc-Depreoptide NeoTect  V Neuroendocrine 
Tumors 
Table 2. Summary of Notable Tc Pharmaceuticals 
 
 
99mTc-Depreotide was the next technetium labelled peptide to enter the clinic, and shows 
affinity for the somatostatin receptor. This agent thus has the ability to imaging neuroendocrine 
tumors. This agent proved interesting due to the observation of syn and anti diasteromers upon 
complexation with Tc. 31 
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 Imaging the brain proved to be difficult when the blood brain barrier is intact. This 
barrier separates circulating blood from extracellular fluid in the central nervous system. The 
semipermeable barrier allows for the passage of certain molecules depending on their size, 
charge, and lipophilicity. Generally, molecules must be small neutral and lipophilic. However, 
the requirements for each parameter are quite arbitrary; therefore. radiopharmaceuticals that 
aspire to image the brain must be highly optimized. There are a couple of Tc 
radiopharmaceuticals that are used clinically to image defects in the brain. 99mTc-HMPAO, also 
known as CeretecTM, and 99mTc-ECD, NeuroliteTM, are agents that detect regional cerebral blood 
flow changes. Both utilize 99mTc in the +5 oxidation state and exploit the 99mTc=O3+ core. The 
ligands are tetradentate and contain a nthiolate-namide (n=2,4) complexation site.  
 One first generation Tc radiopharmaceutical used to image bone infarction and bone 
diseases is 99mTc-MDP. Though there are various complexes involving technetium and 
phosphonates, 99mTc-MDP is the most noteworthy. The complexation is thought to involve Tc 
coordinating to a diphosphonate system through the oxygen. There is very little information 
reported on the structure of Tc-phosphonates with the exception of x-ray crystallography of 
polymeric [Tc(OH)(MDP)]. In this structure, the Tc is octahedral, and oxygen atoms of the 
phosphonate bridge the Tc atoms with an additional oxygen bridge from a hydroxy ligand. 
Despite the discovery of this structural information the oxidation state of the complex is still 
unknown, though thought to be a +3/+4 mixture.32 
 A second-generation Tc radiopharmaceutical used to evaluate kidney function is 99mTc-
Mercaptoacetyltriglycine(Tc-MAG3). Tc-MAG3 was developed as an alternative to o-radioiodo-
hippurate because radiopharmaceuticals with high tubular secretion were needed for optimal 
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renal imaging.33 It was thought that the free carboxylate group would promote more efficient 
renal clearance. Upon coordination, the Tc=O3+ core the three amide nitrogens and the thiolate 
sulfur are deprotonated producing an anionic complex with a square pyramidal complex, with 
the Tc-oxo group in the apical position.27  
 The study of how blood flows through the heart has been a routine procedure in nuclear 
medicine which began using 201Tl-Cl, however due to the relatively long half-life, 3.05 day 
imaging was not optimal. Thus, several Tc-agents were developed. Commercially known as 
CardioliteTM, 99mTc-MIBI, is an FDA approved imaging agent derived from the hexakis isonitrile 
family of compounds.27 The ligands are coordinated through the carbon on the nitrile group and 
the Tc has a +1 oxidation state. Myocardial perfusion imaging agents where the Tc is in the +5 
oxidation state include, MyoviewTM, a trans-dioxo technetium bisphosphine complex.27 There 
are two agents that possess a +3 oxidation state: CardiotecTM, 99mTc-teboroxime cryptate, and 
TechneScan Q12, which is a mixed ligand complex containing Schiff-base bisphosphine.27  
1.4. Rhenium Chemistry and 188Re Radiopharmaceuticals 
 Rhenium is a third-row transition metal typically used as a surrogate for technetium due 
to its similar chemistry. There are two naturally occurring isotopes, 185Re (37.4%) and 187Re 
(62.6%), which were discovered by the Noddacks in 1925.34 Rhenium is used as a 
nonradioactive analog to technetium simply for handling purposes during synthetic and 
analytical chemistry. It is an ideal candidate found just below technetium on the periodic table 
and is predicted to have similar physical characteristics, like size and lipophilicity. Due to the 
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‘lanthanide contraction’ the two have nearly equivalent ionic radii thus suggesting that they 
should have complementary bond parameters. 
  Despite their similarities in practice their differences can have a significant impact. 
Perrhenate has a considerably higher reduction potential than pertechnetate (-0.361 V versus -
0.548 V respectively).26 Generally rhenium complexes are harder to reduce and easier to oxidize 
which causes difficulties when replicating technetium chemistry. This is especially apparent 
when working with tracer-level radioactive rhenium. 
 Currently there are over 30 isotopes of rhenium several of which have characteristics 
optimal for nuclear medicine, particularly radiotherapy. Radiotherapy gives 
radiopharmaceuticals a huge advantage by their ability to destroy rapidly growing cells. The 
isotope186Re has shown promise for its use as a therapeutic agent (half-life= 90 hrs, β- max= 
1.07 MeV, 5 mm range.). It is produced in a nuclear reactor by the neutron irradiation of 185Re, 
185Re(n,γ)186Re, and decays to stable osmium. Though production is limited to reactors due to 
its long half-life 186Re can still be transported and available to isolated sites. SPECT imaging can 
be performed by exploiting the 136 keV (9%) gamma emission. Presently 186Re is used clinically 
as a therapeutic agent for the treatment of bone pain, from bone metastases.35, 36 
 188Re (half-life= 16.9 hrs, β- max= 2.12 MeV, 11 mm range) is another isotope of interest 
as a theragnostic agent, that is a radiopharmaceutical with imaging and therapeutic capabilities. 
The gamma emission, 155 keV (15%), is more applicable than the 186Re isomer, since the 
emission is more abundant and the energies are similar to 99mTc. The isotope 188Re is produced 
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from a 188W/188Re generator. Currently there are several 188Re radiopharmaceuticals that are in 
clinical or preclinical trials tabulated below.37 
 
 
 
Table 3. Current Preclinical and Clinical Trials with 
188
Re-labelled Agents
37
 
188Re Agent Application Instiution
188Re-HEDP
Bone Pain 
Palliation
Bronn and Dresden Germany 
Montevideo, Uruguay; Szeged, 
Hungary; Athens, Greece
188ReV-DMSA
Bone Pain 
Palliation
Kent and Canterbury Hospital, 
Great Britain
188Re-MAG3
Endovascular 
Radiation 
Therapy
Cedars Sinai Medical Center, Los 
Angeles; Perth Australia
188Re-Peptides Tumor Therapy Preclinical- Bonn, Germany
188Re-Particles
Endoradiation 
of Tumors- 
Catheter 
Administration
Preclinical- Dresden, Germany; 
Seoul Republic of Korea; Kaichung, 
Taiwan
188Re-Labelled 
Antigranulocyte 
Antibodies
Marrow 
Ablation Prior 
to Stem Cell 
Rescue
Ulm, Germany
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1.5.  Ligands, Linkers, Targeting Vectors, Pre-Targeting 
 Radiopharmaceuticals containing transition metals must use ligands that incorporate 
the metal into the framework. Ligands often called chelators are organic compounds that house 
metals through coordination of donor atoms. Ligands are chosen based on their in-situ 
biological behavior, and are used in the complexation with various radionuclides for imaging 
and therapy. Peptides are biologically active ligands comprised of amino acids. An advantage 
for using peptides is that they can mimic or replicate biological functions that naturally occur. 
Exploiting this advantage allows peptides to serve in two manners; as a biological vehicle where 
the molecule itself is the targeting vector, and as a bifunctional chelator (BFC). Bifunctional 
chelators are organic compounds that bind to a radiometal and are conjugated to a targeting 
vector or biologically active molecule for target specific imaging.  
 Monoclonal antibodies (mAbs) are targeting vectors that offer highly selective binding 
and affinity for the recognition of virtually an antigen thus represent essential molecules for 
diagnostic and therapeutic applications. 38-40 Antibodies generally exhibit slow distribution 
kinetics, and slow clearance from the body. 41, 42 The multiday biological half-life of an antibody 
necessitates the use of radioisotopes with comparable physical half-lives such as 89Zr (half-life= 
3.2 d) and 124I (half-life= 4.2 d), which can lead to high radiation doses to healthy organs 
ultimately decreasing their desirability for noninvasive imaging of cancer biomarkers.43-45 Due 
to the short half-life, 99mTc is not practical for use in imaging when linked to antibodies, but 
99mTc has been used clinically with antibodies to image cancers and melanomas by using 
antibody fragments that exhibit short circulation time. 46 
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 In order to circumvent the long biological half-life of antibodies and the short physical 
half-life of 99mTc pretargeting methodologies have been developed. Pretargeted 
radioimmunoimaging and radioimmunotherapy proceeds by decoupling the monoclonal 
antibody from the radioisotope and injecting the two components separately, essentially 
leading to the synthesis of the radioimmunoconjugate at the target tumor site itself. 47 The 
radioactive component is generally a small molecule that binds to the tumor site and that which 
does not bind will be rapidly excreted.48, 49 An example is where an antibody is covalently 
bonded to streptavidin is injected and allowed to bind to the antigen. Once the residual 
antibody has cleared from the body, a radiometal complexed to biotin is injected and binds to 
the antibody at the antigen site.27  
 There have been attempts at in vivo pretargeting using a variety of bioorthogonal click 
ligations. This bioorthogonal reaction does not interfere with the biological system and must 
form a stable covalent linkage between functional groups at a reasonable rate even when the 
concentrations are low.50, 51 Vugts et al. developed a pretargeting approach based on the 
Staudinger ligation reaction between an azide-bearing antibody and a phosphine-containing 
probe labeled with 68Ga, 89Zr, 177Lu, and 123I, however the product could not be observed in vivo 
due to the reactions slow kinetics of the reaction.52 Rossin et al. were the first to develop a 
pretargeting strategy based on the inverse electron demand Diels-Alder (IEDDA) reaction.53 The 
IEDDA reaction proceeds with a fast rate without the need of a catalyst and displays the 
remarkably promising results among any other bioorthogonal reaction investigated in tumor 
pretargeting.
54, 55 The reaction generally utilizes a trans-cyclooctene (TCO)-labeled antibody 
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and a tetrazine (Tz)-based radioligand.
56, 57 The coupling is irreversible, and forms a stable 
pyridazine product after release of dinitrogen from the reaction intermediate.
58, 59 
 The IEDDA reaction is carried out in 4 steps: (1) the TCO-modified antibody is injected, 
(2) the modified antibody is given a few days to localize at the tumor site and clear from the 
blood, (3) a small Tz based radioligand is injected, and (4) an in vivo click reaction between the 
antibody and radioligand occurs at the tumor site (Figure 8).
60-66
 
 
 
 
Figure 8. Pretargeted Click Chemistry Approach 
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The pretargeting approach allows time for the antibody to accumulate at the site of interest, 
while also clearing from non-target organs, before injection of a radiolabeled coupling partner. 
The radiolabeled coupling partner reacts selectively with the antibody and that which does not 
bind rapidly clears.67, 68 The pharmacokinetics of small-molecule ligands enables the use of 
radioisotopes with short half-lives, such as 99mTc and 188Re, and thus, the pretargeting approach 
can significantly reduce the radiation dose to nontarget organs. Ths isotope 99mTc was selected 
as an imaging radionuclide because of its exceptional 6.02 hrs half-life and γ-radiation 
component of 0.140 MeV allowing for SPECT imaging. Similarly, 188Re was selected as an 
imaging radionuclide because of its 17 hrs half-life and radiation component of 0.155 MeV.69  
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2. Synthesis and Characterization of Re, 99mTc, and 188Re 
Pentapeptides  
2.1. Introduction 
 Advancements in molecular imaging technology have provided opportunities for 
diagnostic and therapeutic procedures, especially using radiolabeled biological molecules.70, 71 
Radioactive isotopes of technetium (Tc) and rhenium (Re) have significant medical application 
because of the nature of their associated radiation and physical half-life properties. Central to 
molecular imaging is the development of imaging probes.71-73 The isotope 99mTc, a pure γ-
emitter, is a major imaging agent used in over 80% of nuclear imaging.74 It has excellent 
physical properties (γ ray= 142 keV, half-life= 6.02 hrs) and is readily obtained from a 99Mo → 
99mTc generator in its pertechnetate form. The low γ ray energy allows for optimal imaging with 
current gamma camera technology, and its short half-life insures that the radiopharmaceutical 
can be injected with minimal radiation burden to the patient.75, 76 Rhenium, the third-row 
transition metal congener of Tc, exhibits similar complexation chemistry to technetium, 
therefore is often used as a surrogate for characterization of 99mTc radiopharmaceuticals. The 
isotope 188Re has excellent properties as a potential radiotherapeutic isotope. It has a half-life 
of 16 hrs, emits a high-energy β– (Emax= 2.11 MeV) that is effective for cell killing, and also 
generates an imageable γ ray of 155 keV that can be used to track the radiotherapeutic 
agent.77-79  
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 Short peptide sequences labeled with 99mTc and 188Re have attracted interest in the 
development of target-specific radiopharmaceuticals.80, 81 Radiolabeled peptides are valuable 
biological tools for tumor imaging and targeted radionuclide therapy because of their favorable 
pharmacokinetics and specific tumor targeting characteristics. Due to their small size, peptides 
generally exhibit rapid pharmacokinetics and are able to penetrate tumors very efficiently.82, 83 
They also exhibit faster blood clearance and lower kidney retention. One can molecularly 
engineer peptides to exhibit desired pharmacokinetic characteristics by changing the peptide 
sequence during solid-phase synthesis or by grafting additional elements such as polyethylene 
glycol (PEG) linkers to the chelate region. The coordination chemistry of the metal will 
determine the geometry and stability of the radiopeptide complex in vivo.24 
 Technetium and rhenium are group VIIB transition metals that share similar 
coordination geometries and form stable peptide complexes with amine and amide nitrogens, 
carboxylate oxygens, and thiolate sulfurs.23, 84 In this work structures of 99mTc, 188Re, and Re 
complexes are investigated focusing on the KYCAR (lysyl-tyrosyl-cystyl-alanyl-arginine) peptide 
sequence. Chelation about the radiometal is N3S, includes three nitrogens (one amine of Lys 
side chain, two amide nitrogens of Tyr and Cys) and one sulfur (the thiol sulfur of Cys) (Figure 
9). 
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Figure 9. KYCAR Ligand 
 
 
 The thiol group has a high affinity for transition metals, a property convenient for labeling 
cysteine-based proteins with 99mTc or 188Re.23, 85, 86 When peptide-based chelators are 
comprised of amino acids containing side chains, chiral centers are incorporated into the 
coordination plane, and diastereomeric complexes are known to form where the M=O group 
(M= Tc, Re) is either syn or anti to the substituents.87, 88 In this work, it was found that two main 
products are formed when KYCAR is radiolabeled with rhenium, and these are purported to be 
the syn and anti diastereomers of [ReO]KYCAR. The two diastereomers are referred to as syn or 
anti with regard to the position of the side chain of Tyr relative to the M=O bond (Figure 10).  
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Figure 10. Anti and Syn Diastereomers of ReO-KYCAR 
 
 
Although stereoisomers of radiopharmaceutical products often have different biodistribution 
behaviors89-92, it was found that working on the tracer level with the 99mTc and 188Re 
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radionuclides renders it difficult to observe the anti peak, therefore only the syn product was 
evaluated to understand its biological behavior and stability. 
 The overall goals of this project were (1) to synthesize the Tc/Re pentapeptide 
complexes, (2) to identify spectroscopic methods for characterization of syn versus anti 
rhenium peptide complexes, (3) to analyze the ex vivo stability, and (4) to assess the biological 
properties of the [99mTcO]KYCAR and [188Re]KYCAR complex in vivo. Details on this effort are 
provided below.  
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2.2. Materials 
 99mTc was obtained via Memorial Sloan Kettering Cancer Center, New York, New York, as 
Na99mTcO4, eluted from a 
99Mo/99mTc Generator. The isotope 188Re was obtained as Na188ReO4 
was eluted from an 188W/188Re generator with saline (0.9% NaCl solution). The 188W/188Re 
generator was purchased from RadioMedix, Houston, Texas, USA. Activity measurements were 
obtained from an Atomic Products Corporation Atomlab 100 Dose Calibrator. The ligand, 
KYCAR, was purchased from United Peptide, Herndon, Virginia, USA. Methanol (MeOH), 
dimethyl sulfoxide (DMSO), HPLC-grade acetonitrile, triflouroacetic acid (TFA), and 0.9% NaCl 
solution were purchased from Fisher Scientific. Tin (II) tartrate 99%, tin (II) chloride dehydrate, 
and d- gluconic acid was purchased from Sigma Aldrich. Deionized water was obtained from a 
0.22μm Millipore filtration system. All in vivo experiments were performed according to 
protocols approved by the Memorial Sloan-Kettering Institutional Animal Care and Use 
Committee. 
2.3. Syntheses 
2.3.1. (Bu4N)[ReOBr4(H2O)]•H2O 
 This rhenium starting material was prepared following the method of Rose et. al.93 
Briefly 14.05 mmol of n-butylphosphine, PBun3, was dissolved in 20 ml CH2Cl2. 14.20 mmol Br2 
was also dissolved in 20 mL CH2Cl2 and added to the above butylphosphine solution dropwise. 
4.06 mmol (Bu4N)ReO4 was dissolved in 20 mL CH2Cl2, to that the butylphosphine solution was 
added and the resulting solution was allowed to stir for 45 minutes. 3 mL cyclohexene, 100 mL 
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diethyl ether, 100 mL pentane was added sequentially. The purple product was collected via 
vacuum filtration, was washed with diethyl ether and allowed to air dry (2.67 g, 3.26 mmol, 
86%). IR (ATR, cm-1) 2959 (s), 2932 (m), 2873 (m), 1466 (s), 1380 (w), 1227 (w), 1103 (vs), 984 
(vs), 903 (vs), 812 (w), 736 (m). 
2.3.2. ReO-KYCAR 
 The KYCAR ligand (0.0403 mmol) was dissolved in 500 μL CH3OH. The above synthesized 
(Bu4N)[ReOBr4(H2O)]•H2O (0.0403 mmol)  was dissolved in 500 μL  CH3OH and added dropwise 
to the ligand. The resulting reddish brown solution was allowed to stir with a stir bar at 200 rpm 
for 10 minutes. Following stirring the solution was allowed to sit at room temperature for 30 
minutes. The ReO-KYCAR product was analyzed and purified via HPLC with a yield of 40%. 
2.3.3. ReO-KYC 
 The KYC ligand (0.0403 mmol) was dissolved in 500 μL CH3OH. The above synthesized 
(Bu4N)[ReOBr4(H2O)]•H2O (0.0403 mmol)  was dissolved in 500 μL  CH3OH and added dropwise 
to the ligand. The resulting reddish brown solution was allowed to stir with a stir bar at 200 rpm 
for 10 minutes. Following stirring the solution was allowed to sit at room temperature for 40 
minutes. The ReO-KYC product was analyzed and purified via HPLC. 
2.3.4. 99mTcO-KYCAR 
 To a saline solution of 99mTc pertechnetate, KYCAR ligand (200 μL, 0.00234 mmol 
solution) in saline was added. To that mixture tin(II) tartrate (40 μL, 0.0221 mmol solution) in 
water was added and vortexed.  The reaction mixture was then kept at 90° C for 10 minutes 
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followed by sitting at room temperature for 30 minutes. The solution was then filtered through 
a 0.1 μm syringe filter and analyzed or purified via HPLC. Radiochemical Purity 99.9%. 
2.3.5. 188ReO-KYCAR 
 To a saline solution of 188Re perrhenate solution, tin (II) chloride (75 μL, 0.105 mmol 
solution) in water and d-gluconic acid (150 μL, 0.102 mmol solution) in water were added. The 
reaction mixture was vortexed and kept at 37° C for 30 minutes. To this solution the KYCAR 
ligand (200 μL, 0.00313 mmol solution) in saline was added, the reaction mixture was vortexed 
and kept at 37° C for 30 minutes. The solution was then filtered through a 0.1 μm syringe filter 
and analyzed or purified via HPLC. Radiochemical Purity 99.9%. 
2.4. HPLC Analyses 
 Complexes were analyzed using a Waters Symmetry C18 3.5 μm 100 Å analytical column 
4.6 x 150 mm. Complexes were purified using a semi-preparative Waters Nova Pak HR C18 6 μm 
60 Å column 19 x 300 mm. All non-radioactive Re “cold” HPLC experiments were conducted on 
a Rainin HPXL solvent delivery system. Radioactive 99mTc, 188Re “hot” HPLC experiments were 
completed using a Varian Pro Star HPLC system. The radioactive complexes were analyzed and 
purified using a Waters Atlantis dc18 3 μm 100 Å column 4.6 x 150 mm. The γ emissions were 
monitored using a Bicron 2m2/2 NaI detector and Tennelec Minibin components. The software 
used for all HPLC systems was the ProStar WorkStation. The solvents used were ultra-pure 
deionized water with 0.1% trifluoroacetic acid (solvent A), and HPLC-grade acetonitrile with 
0.1% trifluoroacetic acid (solvent B). Method 1 describes the mobile phase gradient for cold 
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HPLC experiments. Method 1: 5-25% B over 26 minutes. Method 2 describes the mobile phase 
gradient for hot HPLC experiments. Method 2: 5-25% B over 20 minutes. The flow rate for 
analytical analyses was 1 mL/minute, and for semi-preparative separations 16.69 mL/minute. 
For all HPLC analyses the UV detection was monitored at 280 nm. 
 For complexes containing stable rhenium the solvent was blown off using N2 for about 4 
hours. The dry complex was then reconstituted in a 95%/5% (solvent A/ solvent B) mixture of 
the mobile phase for HPLC analysis. For complexes containing radioactive metal cores the 
complexes were analyzed upon completion of the syntheses in saline solution. 
2.5. Mass Spectrometry Analysis 
 For cold rhenium compounds, mass spectral data were obtained on a LCMS system 
comprised of an Agilent 1200 LC system coupled to an Agilent 6340 ion trap mass 
spectrometer. Samples were injected onto an Agilent Zorbax column (SB-C8, 5 uM, 2.1 x 50 
mm) using a linear gradient of 5-95% acetonitrile in water (0.5% formic acid) over 10 minutes. 
The samples were prepared by dissolving the lyophilized ReO-KYCAR samples in 
water:acetonitrile solution (v:v, 450:50 μL). 
2.6. NMR Analysis 
 The 1D proton and 2D TOCSY (total correlation spectroscopy) NMR spectra were 
obtained from a Bruker Avance III 600 MHz with a TCI cryoprobe NMR spectrometer with 
chemical shift referenced to H2O, at T=296 K. ReO-KYCAR samples (peak 1, anti, and peak 2, 
syn) (5-10 mg) was dissolved in an 800 μL solution of 0.01 M HCl/D2O 50:50 (v:v). The solution 
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was then transferred to a 5 mm U-Thin NMR tube. 1D proton NMR spectra were collected at 8 
scans. 2D COSY scans were collected at 2 scans, 256 increments. 
 Techniques used for the titration studies are described by Cantorias et. al.88 Briefly 10 
mg of the cold rhenium complex was dissolved in 700 μL 0.01 M DCl in D2O. The pH was 
recorded, the solution was transferred to a 5 mm U-Thin NMR tube, and 1D proton and 2D 
COSY (correlation spectroscopy) NMR spectra were obtained. The sample was then titrated 
with 0.05 M NaOD until the pH changed from 0.5 to 1 intervals. The volume and pH was 
recorded, and NMR spectra were obtained. 
2.7. Infrared Spectroscopy 
 Infrared spectra were obtained using a Perkin-Elmer Spectrum Two IR Spectrometer 
with attached UATR in the range of 500-4000 nm. Briefly a small amount of lyophilized sample 
was placed on the UATR and the appropriate pressure was applied. 
2.8. Circular Dichroism Analysis 
 Circular Dichroism spectra were collected on an Aviv Biomedical Circular Dichroism 
spectrometer of approximately 1 nanomol solutions of Re-KYCAR in 1 mL methanol. The 
samples were scanned from 200 to 680 nm. The samples analyzed were peak 1 and peak 2 from 
the HPLC prep purification 
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2.9. Crystallization  
  Several different techniques were attempted to grow crystals of ReO-KYCAR. For 
each technique, the polar solvents used were as followed; H2O, MeOH, EtOH, acetonitrile, 
ethylene glycol, or ethyl acetate. The nonpolar solvents used were; toluene, pentane, diethyl 
ether or dicholoromethane. Technique 1: solvent evaporation. A 2 mg lyophilized sample was 
dissolved in a 3 mL vial with a minimal amount of polar solvent. A few drops of nonpolar solvent 
were added to the solution and the solution was allowed to sit at room temperature and 
monitored over time. Technique 2: vapor diffusion. A 2 mg lyophilized sample was dissolved in 
in a 3 mL vial with minimal amount of polar solvent and covered with perforated parafilm. The 
3 mL vial was then placed into a 20 mL scintillation vial filled with 3 mL of the non-polar solvent. 
The solvent chamber was then allowed to stand at 4° C and monitored over time. Technique 3: 
purification recrystallization. A 2 mg of lyophilized sample was dissolved in minimal MeOH and 
precipitated with diethyl ether. The solution was centrifuged and the resulting pellet was 
dissolved in a minimal amount of polar solvent. A few drops of nonpolar solvent were added to 
the solution and the solution was allowed to sit at room temperature and monitored over time. 
 Crystals of ReO-KYC were obtained by supersaturation in methanol over 1 week at room 
temperature. 
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2.10. X-ray Structure Determination 
 X-ray diffraction data were collected on a Bruker X8 Kappa Apex II diffractometer. The 
structure was solved using direct methods and standard difference map techniques, and was 
refined by a full-matrix least-squares procedures on F2 with SHELXTL (version 2014/7)  
2.11. LogD Studies 
 To determine the extinction coefficients the radioactive metal (99mTc, 188Re) complexes 
dried via high vacuum system following synthesis. The product was reconstituted in PBS and 
placed into a micro centrifuge tube with an equal amount of 1 octanol. The samples were 
vortexed followed by centrifugation at 10,000 rpm for 5 minutes.  
2.12. Biodistribution Studies 
 The 99mTc and 188Re labelled KYCAR complexes were evaluated for their biological 
distribution in healthy athymic nude female mice 6-8 weeks old. About 100 µCi to 200 µCi (3.7 
X103 - 7.4 X103 kBq) of the radiolabeled complex was injected intravenously into the mice via 
the tail vein. Mice were sacrificed 30 minutes, 1 hour, 2 hour, and 4 hour post injection; 5 mice 
per time point.  The following tissues were collected; blood, heart, lungs, liver, spleen, stomach, 
small intestines, large intestines, kidneys, muscle, bone, skin, thyroid, and gall bladder. The 
tissues were then counted on a Perkin Elmer Automatic Wizard γ-counter and the percent 
injected dose per gram (%ID/g) were calculated and reported. The %ID/g is the amount of 
activity found in a specific tissue divided by the total amount of activity injected multiplied by 
100. 
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2.13. Results and Discussion 
2.13.1. Synthesis and Isolation of 99mTc, 188Re, and Re KYCAR Complexes 
2.13.1.1. Kinetic studies 
 The reaction of ReVOBr4
- with the KYCAR pentapeptide in methanol resulted in two 
major [ReVO] complexes. Rhenium contains a closed-shell d2 electronic configuration that 
readily accepts π electron density during reactions with deprotonated amides and thiol groups 
from peptide ligands. The reversed phase HPLC data in figure 11 shows the kinetics of the 
reaction over a period of 10 days. The reversed phase HPLC data shows 3 peaks present 
immediately post synthesis, denoted peak A, B, and C. Peak A is classified as the intermediate 
peak, as it disappears over time. Peak B and C are the two major peaks. Peak B began to 
convert into peak C so that after 1 day; these peaks were formed in an approximately 2.1:1 
ratio. After 3 days, the ratio was approximately 1:1. The two major complexes reached 
equilibrium 7 days post synthesis, where peak C was the dominant peak at a ratio of 
approximately 0.8:1. It is postulated that the two major peaks represent diastereomers, syn 
and anti, based on previous work in the literature.31, 88 This is further examined and confirmed, 
vide infra. 
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Figure 11. Kinetic study of ReO-KYCAR over 10 day period. Immediately post synthesis there are three peak present 
(A,B,C). Peak A (intermediate peak) converts to peak B (peak 1), which converts to peak C (peak 2). 
 
 
 To further characterize all species formed, peaks A, B, and C were collected separately 
after 1 day via Method 1 and lyophilized to powders. After lyophilization, the powders from 
both the peak A and B products exhibited a peach color, whereas the powder from peak C was 
darker, exhibiting a pinkish/peach color. Initially, we hypothesized that peaks B and C were 
diastereomers, however that was not consistent with mass spectral data. Peak B revealed a 
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molecular ion [M + H]+ peak at m/z 840, which is consistent with the exact mass of the 
[RevO]KYCAR complex (mass= 839.24 g/mol) (Figure 12). 
 
 
 
Figure 12. Mass spectroscopy of ReO-KYCAR peak B molecular ion [M + H]
+
 peak at m/z 840 which corresponds to 
an exact mass of 839.24 g/mol. 
 
 
 Peak C, however, revealed a molecular ion [M + H]+ peak at m/z 854, which is 14 dalton above 
the exact mass of ReO-KYCAR. Peak A contained a mixture of the peaks at m/z 840 and 854. 
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Knowing the reactivity of our peptide, specifically at the carboxyl terminus on the arginine, it 
was theorized that an acid-catalyzed esterification between methanol and the carboxylic acid 
occurred rapidly after synthesis, resulting in a methyl ester adduct (+14 adduct) (Figure 13, 14). 
 
 
 
Figure 13. Structure of ReO-KYCAR + Methyl Ester Adduct 
 
 
Methyl Ester 
Adduct 
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Figure 14. Mass Spectroscopy of ReO-KYCAR + Methyl Ester Adduct 
 
 
  To observe whether peak C could be isolated at m/z 840, it was collected 2 hours post 
synthesis via HPLC and lyophilized. The mass spectral data revealed a 1:2 ratio of m/z 840:854, 
revealing its rapid conversion to the adduct peak C. 
 To test whether methanol promotes this esterification, the reaction was performed in 
acetonitrile. Following the same synthetic procedure, KYCAR was dissolved in 500 μL 
acetonitrile and (Bu4N)[ReOBr4(H2O)]•H20 with 5 drops of deionized water to ensure complete 
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dissolution. After allowing the reaction to sit for 1 day 100 μL of the reaction solution was 
injected onto the HPLC via Method 1 (Figure 15). 
 
 
 
Figure 15. Kinetic study ReO-KYCAR in acetonitrile. Initially reveals three peaks (A, B, and C). Shows that peak B 
does not interconvert to peak C 
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 After collecting and lyophilizing peaks B and C at day one, mass spectral data were 
obtained. Peak B retained the same m/z at 840. More importantly, peak C displayed a signal at 
m/z 840, with no additional mass at m/z 854, thus contributing to our hypothesis that methanol 
reacted with our metal-peptide complex. A kinetic study of the [RevO]KYCAR dissolved in 
acetonitrile (Figure 15) reveals that peak B does not interconvert into peak C. One possible 
explanation for this may be that the use of organic solvents minimizes the interconversion of 
diastereomeric species. 
 
2.13.1.2. 99mTc and 188Re HPLC 
 The reaction of the KYCAR ligand with 99mTcO4
- reduced with tin(II) tartrate results in 
one major complex. Figure 16 shows the immediate post synthesis reverse phase HPLC trace. It 
is hypothesized that this single species occurs due to the extended heating/ reaction time 
during the synthesis. Instant thin layer chromatography shows that the purity post HPLC 
purification is 99.9%. 
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Figure 16. HPLC Trace 99mTcO-KYCAR. 
 
 
 The purified 99mTcO-KYCAR was then coeluted with the macroscopic ReO-KYCAR 
lyophilized peak1 (anti) and is shown in figure 17. This shows the macroscopic rhenium complex 
eluting between 9 and 12 minutes and the tracer technetium complex eluting between 10 and 
12.5 minutes. Due to the location and sequence of the UV and radio detectors in this HPLC 
system UV active species should elute 30 second to 1 minute before radio detection. We note 
that the shoulder appears in the radiotrace at 10 minutes, this co-elutes with the ReO-KYCAR 
and is assigned to the “anti” 99mTc diastereomer. The majority of the 99mTcO-KYCAR is assigned 
to the “syn” diastereomer. The first radiotrace peak (anti diastereomer) likely occurs due to the 
orders of magnitude of macroscopic, carrier ReO-KYCAR.  
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 Figure 17. Coelution of 
99m
TcO-KYCAR with ReO-KYCAR Peak 1(anti)  
 
 
 The reaction of 188ReO4
- reduced with tin (II) chloride with the KYCAR ligand in the 
presence of d-gluconic acid as an exchange ligand also results in major complex. Figure 18 
shows the immediate post synthesis reverse phase HPLC trace. Instant thin layer 
chromatography demonstrates that the purity post HPLC purification is 99.9%. 
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Figure 18. HPLC Trace of 
188
ReO-KYCAR 
 
 
 
Figure 19. Coelution of 
188
ReO-KYCAR with ReO-KYCAR 
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The purified 188ReO-KYCAR was then coeluted with the macroscopic ReO-KYCAR lyophilized 
peak1 (anti) and is shown in Figure 19. This shows the macroscopic rhenium complex eluting 
between 7 and 11 minutes and the tracer rhenium complex eluting between 8 and 12 minutes. 
Due to the location and sequence of the UV and radio detectors in this HPLC system the UV 
active species should elute 30 second to 1 minute before radio detection. Therefore, it is 
observed that the two complexes are chemically identical. The 188Re is less stable than its 99mTc 
congener, which is observed by the slight decomposition to 188ReO4
-. There appears to be small 
amounts of other decomposition products as seen by the radiopeak at 4.5 minutes and 145 
minutes.  
2.13.2. Spectroscopic Characteristics 
2.13.2.1. NMR 
 The chemical shifts from the 1H NMR spectra of the macroscopic ReO-KYCAR 
diastereomers (Table 4) were compared to the free KYCAR ligand. This allows assignment of the 
protons of the diastereomers (Figure 20). For reference Figure 21 labels the amino acids within 
the ligand by its 1-letter code. 
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Figure 20. Structures of ReO-KYCAR diastereomers (Anti and Syn) 
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Figure 21. ReO-KYCAR Structure Labelled with 1-letter Amino Acid Code 
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Table 4. 
1
H NMR of KYCAR, ReO-KYCAR peak 1, ReO-KYCAR peak 2, and the change (Δ) in ppm between peak 1 and 
peak 2 
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The deprotonation of the amide groups was immediately observed on the tyrosine and cysteine 
residues, thus showing the coordination to the Re-oxo core. The β-proton of the lysine shows 
two resonances in the complex resulting from the change in electron density due to the 
complexation to the metal core. The β-proton of the cysteine also shows two resonances due to 
the deprotonation of the thiol. 
 As seen previously in the literature, typically technetium(V)-oxo complexes carry a 
square pyramidal structure with the metal oxo group in the apical position when complexed to 
a tetradentate ligand.94-96 It is postulated that the peak 1, or the anti isomer, has the lysine side 
chain opposite the Re-oxo core and on opposite sides of the plane. Therefore peak 2, or the syn 
isomer, has the lysine side chain and the Re-oxo core on the same side of the plane. To further 
confirm this, the chemical shifts for the syn isomer are all located downfield in comparison to 
the anti isomer and the free KYCAR ligand, which correlates to the desheilding effect imposed 
by the Re-oxo core. To assist in the deconvolution of the 1H chemical shifts, 2D TOCSY spectra 
were obtained. Formation of the lysine and cysteine β-proton resonances is also observed 
(Figures 22, 23).  
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Figure 22. ReO-KYCAR Peak 2 (Syn) Downfield Aliphatic TOCSY 
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Figure 23. ReO-KYCAR Peak 2 (syn) Upfield Aliphatic TOCSY 
 
 NMR titration curves were used to determine the pKa’s of specific residues on ReO-
KYCAR and the free KYCAR ligand. For this study, it was decided to monitor the Hα and the Hε 
found on the lysine of each construct (Figure 24 and 25).  
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Figure 24. NMR Titration Curve for ReO-KYCAR. Connected dots represent the lysine alpha proton, and the connected squares 
represent the lysine epsilon protons. 
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Figure 25. NMR Titration Curve for the free KYCAR ligand. Connected dots represent the lysine alpha proton, and the connected 
squares represent the lysine epsilon protons. 
 
 
To determine the pKa values a NMR titration procedure described by Rose et. al.
93. Briefly the 
values were determined by plotting pH vs. 100[(σobs-σHL)/ (σL- σHL)]. Here σobs is the chemical 
shift at a specific pH; σHL is the chemical shift of the highest pH; σL is the chemical shift of the 
lowest pH. Below are tables summarizing the calculation (Tables 5-8) and figures highlighting 
the plots and the pKa values (Figures 26-29) 
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Table 5. Chemical shifts (middle column) of the alpha proton on the lysine of ReO-KYCAR at various pH. The first and last 
columns represent the x and y axes for the following figure. 
 
 
pH δ, ppm of KHα 100[δobs-δHL)/(δL-δHL)
1.8 3.965 0.0
2.34 3.969 5.2
2.91 3.97 6.5
3.55 3.971 7.8
4.07 3.972 9.1
4.58 3.976 14.3
5.19 3.982 22.1
5.78 3.995 39.0
6.43 4.025 77.9
7.17 4.042 100.0
8.34 4.045 103.9
9.13 4.045 103.9
10.01 4.042 100.0
ReO-KYCAR KHalpha
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Figure 26. NMR titration curve for ReO-KYCAR alpha proton on the lysine. pKa=6.00 plotted by Prism via sigmoidal curve fit. Free 
solid dots represent experimental data points, dashed and solid lines are representative of the sigmoidal curve fit. 
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Table 6. Chemical shifts (middle column) of the epsilon proton on the lysine of ReO-KYCAR at various pH. The first and last 
columns represent the x and y axes for the following figure. 
 
 
pH δ, ppm of KHε 100[δobs-δHL)/(δL-δHL)
1.8 2.92 0.0
2.34 2.924 -5.6
2.91 2.926 -8.3
3.55 2.926 -8.3
4.07 2.926 -8.3
4.58 2.926 -8.3
5.19 2.923 -4.2
5.78 2.91 13.9
6.43 2.894 36.1
7.17 2.883 51.4
8.34 2.88 55.6
9.13 2.875 62.5
10.01 2.848 100.0
ReO-KYCAR KHepsilon
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Figure 27. NMR titration curve for ReO-KYCAR epsilon proton on the lysine. pKa=7.53 plotted by Prism via sigmoidal curve fit. 
Free solid dots represent experimental data points, dashed and solid lines are representative of the sigmoidal curve fit. 
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Table 7. Chemical shifts (middle column) of the alpha proton on the lysine of free KYCAR at various pH. The first and last columns 
represent the x and y axes for the following figure. 
 
 
pH δ, ppm of KHα 100[δobs-δHL)/(δL-δHL)
1.91 3.856 0.0
2.57 3.858 -0.3
3.28 3.86 -0.6
3.97 3.86 -0.6
4.54 3.86 -0.6
5.27 3.854 0.3
6.01 3.82 5.8
6.65 3.737 19.1
7.19 3.64 34.7
7.85 3.411 71.5
8.54 3.267 94.7
9.17 3.234 100.0
KYCAR KHalpha
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Figure 28. NMR titration curve for free KYCAR alpha proton on the lysine. pKa=7.48 plotted by Prism via sigmoidal curve fit. Free 
solid dots represent experimental data points, dashed and solid lines are representative of the sigmoidal curve fit. 
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Table 8. Chemical shifts (middle column) of the epsilon proton on the lysine of free KYCAR at various pH. The first and last 
columns represent the x and y axes for the following figure. 
pH δ, ppm of KHε 100[δobs-δHL)/(δL-δHL)
1.91 2.845 0.0
2.57 2.847 -2.1
3.28 2.847 -2.1
3.97 2.847 -2.1
4.54 2.849 -4.2
5.27 2.849 -4.2
6.01 2.845 0.0
6.65 2.84 5.3
7.19 2.847 -2.1
7.85 2.831 14.7
8.54 2.814 32.6
9.17 2.8 47.4
10.1 2.75 100.0
KYCAR KHepsilon
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Figure 29. NMR titration curve for free KYCAR epsilon proton on the lysine. pKa=10.28 plotted by Prism via sigmoidal curve fit. 
Free solid dots represent experimental data points, dashed and solid lines are representative of the sigmoidal curve fit. 
 
 
In the free ligand, it was determined that the pKa’s of the alpha proton and the epsilon proton 
on the lysine were 7.48 and 10.28 respectively. Also, the pKa’s of the alpha proton and the 
epsilon proton on the lysine of ReO-KYCAR were 6.00 and 7.53 respectively. Due to the lower 
pKa values for the alpha proton on the lysine of ReO-KYCAR, it is hypothesized that there may 
be an interaction between the Re=O core and the Re-N bonds that could facilitate the 
deprotonation of the NH2 terminus on the lysine. This would create a Re-Namide bond for the 
lysine N-terminus of the peptide. The Re-Namide bond would carry a negative charge and this 
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suggests that under physiological pH, the chelator region of the ReO-KYCAR is negatively 
charged.  
2.13.2.2. Infrared Spectroscopy 
 The infrared spectra for the anti and syn peaks C indicates a Re=O stretching frequency 
at 991 cm-1 and 990 cm-1, respectively. These values are slightly shifted to higher energies to 
984 cm-1, which was observed from (Bu4N)[ReOBr4(H2O)]•H2O, indicating that the Re=O bond 
from peaks B and C exhibit slightly more double bond character. The diastereomers also exhibit 
a broad peak at 2800-3500 cm-1, characteristic of the phenol and carboxylic acid O-H and amine 
N-H. Both peaks exhibit a strong intensity stretching frequency at around 1649 cm-1 (anti) and 
1654 cm-1 (syn), indicative of the C=O secondary amide bond, specifically representing an amide 
I band. New medium intensity stretching frequencies at 1515 cm-1 (anti) and 1514 cm-1 (syn) are 
characteristic of our secondary amide as well, specifically corresponding to an amide II band. 
 The last new major peak that appears in ReKYCAR exhibits a strong intensity stretching 
frequency at 1199 cm-1 (anti) and 1198 cm-1 (syn), corresponding to the secondary amide C=O 
amide III band. For the syn peak specifically, a stretching frequency characteristic of a C=O ester 
band as our NMR confirmed is expected. It is believed that the ester carbonyl stretch shifted 
and overlaps with the amide carbonyl stretch at 1654 cm-1 because the infrared spectra of the 
syn peak reveals that there are actually 2 peaks at around 1654 cm-1, whereas the infrared 
spectra of the anti isomer exhibits only 1 peak at 1649 cm-1. This double peak indicates that the 
ester and amide carbonyl stretches are overlapping (Figure 30). 
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Figure 30. IR Spec. of KYCAR(Top), Re starting material, ReO-KYCAR peak 1, ReO-KYCAR peak 2(Bottom) 
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2.13.2.3. Circular Dichroism 
 To observe structural signatures of each of the isolated peaks, peaks 1 (anti) and peak 2 
(syn), CD spectra were obtained and are shown below (Figure 31). 
 
 
 
Figure 31. Circular Dichorism of ReO-KYCAR Peak 1(anti) (Black), and ReO-KYCAR Peak 2 (syn) (Blue) 
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 The areas that provide the most information lie between 280 and 340 nm. Within this 
region are transitions, which include ligand to metal charge transfer. According to previous 
studies on rhenium-Schiff base complexes, this region correlates to the oxygen to rhenium 
charge transfer transitions.97, 98 The strong positive Cotton effect, or characteristic change in 
optical rotatory, around 280 nm is assigned to the Re-oxo core in the anti positon. Conversely, 
we see a negative Cotton effect of the Re-oxo core in the syn position. The postulated anti and 
syn circular dichroism spectra can be confirmed by comparing this CD data to previously 
reported data showing anti and syn complexes with crystallographically characterized Re-and Tc 
peptides (Figure 32).88 
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Figure 32. Comparison of Previously Reported Anti and Syn Metal-Peptides 
 
 
2.13.2.4. Crystallography  
 The following (Tables 9, 10) shows a summary of crystallization results of peaks 1 and 2 
ReO-KYCAR. The purification crystallization technique yielded a powdery substance along the 
walls of the vial, however the material did not diffract.  The vapor diffusion technique yielded 
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two possible materials. The first was determined to be an oily substance, while the second 
which was crystalline in nature was determined to be rhenium oxide salt covered in an oil of 
our product. 
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Table 9. Summary of Crystallization Results ReO-KYCAR Peak1 (anti) 
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Table 10. Summary of Crystallization Results ReO-KYCAR Peak 2 (syn) 
 
 
 Due to the unsuccessful attempts crystallizing ReO-KYCAR, ReO-KYC-NH2 (ReO-KYC) 
(Figure 33) crystallization was attempted to investigate the structure around the complexation 
region. An amide capped peptide was used to prevent any potential methyl esterification from 
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occurring. Crystals of similar ReO and TcO tripeptide complexes bearing cysteine at the 
carboxylate terminus have been previously obtained and reported in the literature.88 ReO-KYC 
was synthesized and analyzed via reverse phase HPLC (Figure 34). Post synthesis there are two 
major peaks present corresponding to two diastereomers. It is postulated that peak 1 is the anti 
peak and peak 2 is the syn peak. Orange crystals were obtained by supersaturation in methanol 
over 1 week. The crystal and structure refinement data are tabulated in table 11. Bond lengths 
and bond angles are tabulated in table 12, and the Ball and Stick diagrams are shown in Figure 
35. 
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Figure 33. Stucture of ReO-KYC 
 
74 
 
 
Figure 34. Reversed Phase HPLC of ReO-KYC Post Synthesis. Shows 2 major peaks. Peak 1 (anti) and peak 2 (syn) 
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Table 11. Crystal and Structure Refinement Data for ReO-KYC Peak 2 (syn) 
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Table 12. Bond Lengths and Bond Angles for ReO-KYC Peak 2 (Syn) 
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Figure 35. Ball and Stick Diagram for ReO-KYC (syn) 
 
 
 The crystal structure determined that the coordinating nitrogen on the lysine (N3) is an 
amine nitrogen. Also, the molecule exhibits a tetrahedral geometry, as all of the oxygen-
rhenium-nitrogen bond angles fall in the 109.5° range. The crystallization in a non-
centrosymmetric space group confirms that there is only one enantiomer present. 
 The crystals were dissolved and reinjected into the HPLC to confirm which peak 
coordinates with the syn diastereomer (Figure 36). The reversed phase HPLC trace shows that 
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the dissolved crystal corresponds to peak 2. Correlating this data to ReO-KYCAR it can be 
confirmed that peak 2 is also the syn diastereomer. 
 
 
 
Figure 36. Reversed phase HPLC of ReO-KYC syn crysta confirming that peak 2 corresponds to the syn crystal 
structure. 
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2.13.3. Biology 
 The 99mTc-KYCAR and 188Re-KYCAR stabilities in phosphate buffered saline (PBS) (Figure 
37) and human serum (Figure 38) were evaluated in vitro via HPLC analysis. The 99mTcO-KYCAR 
remained relatively stable with very little 99mTcO4
- growing in up to 2 hours. Decomposition of 
the complex to 99mTcO4
- would result in a peak with an elution time of 5 minutes. The in vitro 
incubation of 99mTcO-KYCAR in human serum results in an immediate slight decomposition of 
the complex to 99mTcO4
- and another polar species. Though there is immediate decomposition 
there is no further decomposition up to 2 hours. 
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Figure 37. HPLC of 
99m
TcO-KYCAR (syn) in PBS monitored over time 
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Figure 38. HPLC of 
99m
TcO-KYCAR (syn) in Human Serum monitored over time 
 
 
 The biological distribution of 99mTc-KYCAR and 188Re-KYCAR were of interest to 
understand the uptake of the complexes as well as monitor the degradation in vivo. The 
complexes were HPLC purified, reconstituted with sterile saline and injected into healthy 
athymic nude female mice intravenously. Animals were sacrificed at 30 min, 1 hr, 2 hrs, and 4 
hrs post injection, and the results are summarized below as the percent of the injected dose to 
each selected organ of the mouse (%ID/g) (Table 13, Figure 39).  
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Table 13. 
99m
TcO-KYCAR(syn). The results are reported in %ID/g. Shows that the activity travels through the 
gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 as seen with thyroid accumulation  
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Figure 39. 
99m
TcO-KYCAR(syn). The results are reported in %ID/g. Shows that the activity travels through the 
gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 as seen with thyroid accumulation 
 
 
 99mTc-KYCAR shows high uptake in the liver after 30 minutes (22.10 %ID/g). High liver 
uptake may be due to the large size and structure of the complex. After 4 hours, the 
radioactivity in the liver decreased to 1.83 %ID/g indicating efficient clearance and low amounts 
of accumulation over time in the liver. Concurrently, 99mTc-KYCAR exhibited rapid accumulation 
in the small intestine 30 minutes post injection (22.82%ID/g), with subsequent depletion 4 
hours post injection (3.62 %ID/g). As expected from this trend, levels of the radiotracer in the 
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large intestine increased from 0.31 %ID/g at 30 minutes to 36.77 %ID/g at 4 hours. Thus, it can 
be assumed that the majority of the radioactivity in the intestines arrives and is excreted via the 
hepatobiliary system despite the hydrophilic nature of our radiotracer (logD=-2.631).  
 Uptake and retention of our radioligand is also seen in moderate amounts in the kidneys 
(5.95 %ID/g at 30 min to 4.87 %ID/g at 4 hours) indicating some excretion through the renal 
system. These findings are contradictory to the hypothesis that increased hydrophilicity would 
favor renal excretion over hepatobiliary excretion, but it is believed that the large molecular 
weight of the radiolabeled peptide complex favors this method of excretion. The radioactivity 
accumulation in the stomach for 99mTc-KYCAR decreased with time, showing 4.07 %ID/g 
retained 4 hours post injection, as compared to 4.57 %ID/g at 30 minutes, indicating that the in 
vivo stability correlates well with the high in vitro stability that was previously observed. 
Significantly, low uptake and retention of 99mTc-KYCAR was observed at 4 hours in the heart 
(0.33 %ID/g), lungs (0.99 %ID/g), spleen (0.44 %ID/g) and muscle (0.24 %ID/g). The low level of 
radioactivity in the blood already at 30 minutes (1.77 %ID/g) indicates favorable and rapid 
blood clearance (decreases to 0.91 %ID/g at 4 hour). 
 Figure 40 shows the stability of 188ReO-KYCAR in PBS over time. It shows an immediate 
decomposition of the complex with two peaks. The first peak which elutes at around 5 minutes 
corresponds to 188ReO4
-, and the second is the 188ReO-KYCAR complex. Though the initial 
contact with PBS results in a relatively large amount of decomposition the sub sequential HPLC 
traces show very little growth of the perrhenate peak. The stability of 188ReO-KYCAR in serum is 
particularly interesting in that the complex does not appear to be very stable. After contacting 
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the rhenium complex with human serum for 30 minutes there is only 188ReO4
- present in the 
supernatant (Figure 41). 
 
 
 
Figure 40. HPLC of 
188
ReO-KYCAR (syn) in PBS monitored over time 
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Figure 41. HPLC of 
188
ReO-KYCAR (syn) monitored in Human Serum over time 
 
 
  Despite the in vitro biology results it was important to analyze the behavior of 188ReO-
KYCAR in vivo which is shown (Table 14, Figure 42). Very similar trends are observed with the 
188ReO-KYCAR construct and the 99mTcO-KYCAR. Its logD value of -2.280 reveals that it is slightly 
more hydrophobic than the 99mTcO-KYCAR construct, therefore we expect it to have an 
increased preference for the hepatobiliary pathway. At 30 minutes, radioactivity in the liver is 
17.61 %ID/g, and just as the technetium-labeled pentapeptide, after 4 hours radioactivity 
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decreases to 0.99 %ID/g. There is a large amount of accumulation observed in the intestines, 
similar to the technetium construct. At 30 minutes, the radioactivity in the small intestine is 
33.15 %ID/g, while the radioactivity in the large intestine is expectedly low at 0.38 %ID/g. After 
4 hours, the radioactivity in the small intestine decreases to 0.95 %ID/g, while the radioactivity 
in the large intestine increases to 31.99 %ID/g. Although there is uptake in the kidneys (3.81 
%ID/g at 30 minutes), the amount of uptake is less than it is for 99mTc-KYCAR, corresponding 
with the logD values, and confirming that the rhenium construct is even more inclined to be 
excreted through the hepatobiliary system. Similarly, to the technetium construct, the 
radioactivity accumulation in the stomach for 188Re-KYCAR decreases with time, showing 2.50 
%ID/g retained 4 hours post injection, as compared to 6.24 %ID/g at 30 minutes. Again, this 
indicates that it retains stability and does not decompose to perrhenate at high rates in vivo 
over time. Significantly, the uptake value for all other collected organs is <1%ID/g after 4 hours. 
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Table 14. 
188
ReO-KYCAR (syn) The results are reported in %ID/g. Shows that the activity travels through the 
gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 as seen with thyroid and stomach accumulation 
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Figure 42. 
188
ReO-KYCAR (syn) The results are reported in %ID/g. Shows that the activity travels through the 
gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 as seen with thyroid and stomach accumulation 
 
 
2.14. Conclusion 
 Without crystal structure data, it is difficult to designate specific diastereomers of metal 
peptide complexes. Unfortunately, due to the nature of the KYCAR ligand there were no 
successful crystallization attempts.  Most resulted in amorphous powders or impurity filled oils. 
However, through crystallization of the tripeptide ReO-KYC the diastereomers can be properly 
assigned. It was determined that the crystallized species was in the syn confirmation and 
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correlates to peak 2 in the HPLC trace. From this data, it is also determined that the ReO-KYCAR 
peak 2 is also in the syn confirmation. 
 HPLC results of ReO-KYCAR initially indicate that two isomeric species of the same 
complex may be present with both peaks eluting within a few minutes of each other. IR data 
further conclude that the two isolated species are diastereomers due to the similar stretches 
and frequencies observed in both complexes. 
 However, results obtained from 1H NMR show shifts in the ligand residues that 
correspond to electron density shifts resulting from a change in the position of the Re-oxo core. 
Proton NMR data confirms the complex to the metal core by monitoring the absorption of the 
amide protons of the tyrosine and Cysteine residues. This is also confirmed by the shift in the β-
protons on the lysine side chain resulting from a change in electron density about the chelation 
region. And by the shift in the β-protons on the cysteine side chains due to the deprotonation 
of the thiol. Proton NMR also begins to assign each of the isolated isomers. The data shows that 
the second isolated complex has chemical shifts downfield from the free ligand as well as the 
first peak. The downfield chemical shift correlates to the desheilding effect imposed by the Re-
oxo core. 
 Circular Dichroism data and previous work done on rhenium and various peptides give 
the most solid information into the diastereomers of ReO-KYCAR. Here we see that the first 
eluted complex, the anti peak follows the trend of having a large positive Cotton effect about 
the region that correlates to the oxygen to rhenium charge transfer transitions. Furthermore, 
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the second eluted complex follows the trend of having a negative Cotton effect about the same 
region. 
 Biologically, tracer level complexes (99mTc, 188Re) are both relatively stable under 
biological conditions up to 2 hours, though that are some decomposition products present 
shown by thyroid uptake. 99mTcO-KYCAR shows high uptake in the liver, small intestines and 
large intestines up to 4 hours post injection. This concludes that the complex is excreted via the 
hepatobiliary system despite the hydrophilic nature of our radiotracer. However, there is not a 
large uptake in the stomach and thyroid, which would indicate in vivo decomposition. The 
188ReO-KYCAR complex shows very similar organ uptake to 99mTcO-KYCAR. One noticeable 
difference is the increased uptake in the stomach. Though relatively low it still indicates 
decomposition of the complex. 
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3. 99mTc and 188Re Pretargeting Spect and Radioimmunotherapy 
Agents Employing Bioorthogonal Diels Alder Click Chemistry 
3.1. Introduction 
 Monoclonal antibodies (mAbs) offer highly selective binding and affinity for the 
recognition of virtually any antigen thus represent essential molecules for diagnostic and 
therapeutic applications.38-40 Antibodies generally exhibit slow distribution kinetics and slow 
clearance from the body.41, 42 The multi-day biological half-life of an antibody necessitates the 
use of radioisotopes with comparable physical half-lives, such as 89Zr (t1/2=3.2 d) and 
124I 
(t1/2=4.2 d), which can lead to high radiation doses to healthy organs.
43-45 In order to reduce the 
dose to healthy tissues, pretargeting methodologies have been developed. Pretargeted 
radioimmunoimaging and radioimmunotherapy proceeds by decoupling the monoclonal 
antibody from the radioisotope and injecting the two components separately, essentially 
leading to the synthesis of the radioimmunoconjugate at the target tumor site itself.47 
 There have been attempts at in vivo pretargeting using a variety of bioorthogonal click 
ligations. This biorthogonal reaction does not interfere with the biological system and must 
form a stable covalent linkage between functional groups at a reasonable rate even when 
concentrations are low.50, 51 Vugts et al. developed a pretargeting approach based on the 
Staudinger ligation reaction between an azide-bearing antibody and phosphine-containing 
probe labeled with 68Ga, 89Zr, 177Lu, and 123I, however the product could not be observed in vivo 
due to the reactions slow kinetics of the reaction.52 Rossin et al. were the first to develop a 
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pretargeting strategy based on the inverse electron demand Diels-Alder (IEDDA) reaction.53 The 
IEDDA reaction proceeds with a fast rate without the need of a catalyst and displays the 
remarkably promising results among any other bioorthogonal reaction investigated in tumor 
pretargeting.54, 55 The reaction generally utilizes a TCO-labeled antibody and a tetrazine (Tz)-
based radioligand.56, 57 The coupling is irreversible, and forms a stable pyridazine product after 
release of dinitrogen from the reaction intermediate.58, 59  
 The IEDDA reaction is carried out in 4 steps: (1) the TCO-modified antibody is injected, 
(2) the modified antibody is given a few days to localize at the tumor site and clear from the 
blood, (3) a small Tz based radioligand is injected, and (4) an in vivo click reaction between the 
antibody and radioligand occurs at the tumor site.42, 60-64 This allows time for the antibody to 
accumulate at the site of interest, while also clearing from non-target organs, before injection 
of a radiolabeled coupling partner that reacts selectively with the antibody and allows rapid 
clearance of excess radioactivity.67, 68 The pharmacokinetics of small-molecule ligands enables 
the use of radioisotopes with short half-lives, such as 99mTc and 188Re, and reduces radiation 
dose to nontarget organs. The isotope 99mTc was selected as an imaging radionuclide because of 
its exceptional 6.02 h half-life and γ-radiation component of 0.140 MeV allowing for SPECT 
imaging. Similarly, 188Re is a beta emitter, 2.0 MeV βmax, half-life: 17 hours, and is considered a 
radiotherapy analog to 99mTc. This isotope also possesses an imageable gamma of 0.155 MeV.69 
 This chapter discusses the development of a pretargeted SPECT imaging approach that 
facilitates the rapid inverse electron demand [4+2] Diels-Alder cycloaddition reaction between 
a tetrazine-based radioligand and TCO-labeled antibody. The tetrazines used were tetrazine-
NHS ester, and tetrazine-PEG5-NHS ester (Figure 43, 44) Within the study, the following were 
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used: the SW1222 colorectal cancer cell line, the A33 antibody, and two gamma-emitting 
radiometals 99mTc and 188Re as a model system. Ultimately, we have shown rapid and clear 
visualization of tumor tissue with excellent tumor-to-background activity concentration ratios 
using the in vivo cycloaddition methodology.  
 
 
 
Figure 43. Structure of tetrazine-NHS ester (sh-Tz) 
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Figure 44. Structure tetrazine-PEG5-NHS ester (PEG5-Tz) 
 
3.2. Materials 
 The 99mTc was obtained via Memorial Sloan Kettering Cancer Center, New York, New 
York, as Na99mTcO4, eluted from a 
99Mo/99mTc Generator. The 188Re was obtained as Na188ReO4 
was eluted from an 188W/188Re generator with 0.9% NaCl solution. The 188W/188Re generator 
was purchased from RadioMedix, Houston, Texas, USA. Activity measurements were obtained 
from an Atomic Products Corpration Atomlab 100 Dose Calibrator. The ligand, KYCAR, was 
purchased from United Peptide, Herndon, Virginia, USA. Tetrazine-NHS Ester (sh-Tz) and 
Tetrazine-PEG5-NHS Ester (Tz-PEG5) were purchased from BroadPharm, San Diego, California, 
USA. Isofluorane was purchased from Baxter Healthcare. Humanized A33 antibody was 
provided by the Ludwig Institute for Cancer Immunotherapy. All in vivo experiments were 
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performed according to protocols approved by the Memorial Sloan-Kettering Institutional 
Animal Care and Use Committee. 
 Methanol (MeOH), dimethyl sulfoxide (DMSO), N,N-diisopropylethyl amine (DIEA), 
HPLC-grade acetonitrile, triflouroacetic acid (TFA), 0.9% NaCl solution were purchased from 
Fisher Scientific. Tin (II) tartrate 99%, tin (II) chloride dehydrate, and d- gluconic acid and all 
other chemicals were purchased from Fisher Scientific or Sigma Aldrich. Deionized water was 
obtained from a 0.22μm Millipore filtration system. 
3.3. Synthesis 
3.3.1. ReO-KYCAR 
 The KYCAR Ligand (0.0403 mmol) was dissolved in 500 µL CH3OH. The 
(Bu4N)[ReOBr4(H2O)]•H2O (0.0403 mmol) was dissolved in 500 µL CH3OH and added dropwise 
to the ligand and allowed to stir at 200 rpm for 10 minutes. Following stirring the solution was 
allowed to sit at room temperature for 30 minutes. The ReO-KYCAR (syn) product was analyzed 
and purified via HPLC. Yield 40%. 
3.3.2. 99mTcO-KYCAR 
 To a saline solution of 99mTc pertechnetate, KYCAR ligand (200 µL, 0.00234 mmol 
solution) in saline was added. To that mixture tin(II) tartrate (40 µL, 0.0221 mmol solution) in 
water was added and vortexed. The reaction mixture was then kept at 90°C for 10 minutes 
followed by sitting at room temperature for 30 minutes. The reaction mixture was then filtered 
through a 0.1 µm syringe filter and analyzed via HPLC. Radiochemical Purity 99.9%. 
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3.3.3. 188ReO-KYCAR 
 To a saline solution of 188Re perrhenate solution, tin(II) chloride (75 µL, 0.105 mmol 
solution) in water and d-gluconic acid (150 µL, 0.102 mmol solution) in water were added. The 
reaction mixture was vortexed and kept at 37°C for 30 minutes. To this the KYCAR ligand (150 
µL, 0.03313 mmol solution) in saline was added, the reaction mixture was vortexed and kept at 
37°C for 30 minutes. The solution was then filtered through a 0.1 µm syringe filter and analyzed 
via HPLC. Radiochemical Purity 99.9%. 
3.3.4. Conjugation with Tetrazine-NHS ester and Tetrazine-PEG5-NHS ester 
3.3.4.1. ReO-KYCAR-Sh-Tz and ReO-KYCAR-PEG5-Tz 
 0.013 mmol of purified, lyophilized ReO-KYCAR (syn) was dissolved in 100 µL DMSO. To 
that 0.0013 mmol of desired tetrazine construct in DMSO was added followed by an addition of 
0.04 to 0.09 mmol of DIEA. The reaction was allowed to sit at room temperature for 30 
minutes. The construct was then purified via preparative HPLC. The major peak was collected 
and lyophilized. 
3.3.4.2. 99mTcO-KYCAR-Sh-Tz and 99mTcO-KYCAR-PEG5-Tz 
 99mTcO-KYCAR(syn) (purified as described above) was dissolved in DMSO. To that 0.0007 
mmol of desired tetrazine construct in DMSO was added followed by an addition of 0.0287 
mmol DIEA.  The reaction was allowed to react for 30 minutes at room temperature and 
purified via HPLC. The major fraction was collected and dried down by vacuum. 
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3.3.4.3. 188ReO-KYCAR-Sh-Tz and 188ReO-KYCAR-PEG5-Tz 
 188ReO-KYCAR (syn) (purified as described above) was dissolved in DMSO. To that 0.0007 
mmol of desired tetrazine construct in DMSO was added followed by an addition of 0.0287 
mmol DIEA.  The reaction was allowed to react for 30 minutes at room temperature and 
purified via HPLC. The major fraction was collected and dried down by vacuum. 
3.3.5. A33 Modification with TCO-NHS 
 The A33 antibody was modified with transcyclooctene-NHS following the method of 
Zeglis et. al.66 Briefly 5 mg A33 was dissolved in 500 µL PBS. The pH was adjusted to 8.8 – 8.9 
using 0.1M NaHCO3. To this the adequate amount of TCO-NHS in N,N-dimethylformamide 
(25mg/mL) was added and the solution was mixed at 350 rpm for 1 hour at 25°C. Following 
incubation, the antibody was purified using a size-exclusion Sephadex G-25M PD-10 column 
(2.5 mL dead volume), and concentrated using centrifugal filtration units with a 50,000 
molecular weight cut off. 
3.4. HPLC Analysis 
 HPLC experiments were completed using a Varian Pro Star HPLC system. Complexes 
were analyzed and purified using a Waters Atlantis dc18 3 μm 100 Å column 4.6 x 150 mm.  γ 
emissions were monitored using a Bicron 2m2/2 NaI detector and Tennelec Minibin 
components. The software used for all HPLC systems was the ProStar WorkStation. The solvents 
used were ultra-pure deionized water with 0.1% trifluoroacetic acid (solvent A), and HPLC-
grade acetonitrile with 0.1% trifluoroacetic acid (solvent B). Method: 20-30% B over 25 minutes 
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with a flow rate of 1 mL/minute. For all HPLC analyses the UV detection was monitored at 260 
and 525 nm. 
3.5. Mass Spectrometry Analysis 
 For cold rhenium compounds, mass spectral data were obtained from samples analyzed 
on an LCMS system comprised of an Agilent 1200 LC system coupled to an Agilent 6340 ion trap 
mass spectrometer. Samples were injected onto an Agilent Zorbax column (SB-C8, 5 uM, 2.1 x 
50 mm) using a linear gradient of 5-95% acetonitrile in water (0.5% formic acid) over 10 
minutes. The samples were prepared by dissolving the ReO-KYCAR tetrazine samples in a 
water:acetonitrile solution (v:v, 450:50 μL). 
3.6. Proton NMR Analysis 
 1D proton and 2D COSY (correlation spectroscopy) NMR spectra were obtained from a 
Bruker Avance III 600 MHz with a TCI cryoprobe NMR spectrometer with chemical shift 
referenced to H2O, at T=296 K. The ReO-KYCAR tetrazines (1-5 mg) was dissolved in an 800 μL 
solution of 0.01 M HCl/D2O 50:50 (v:v). The solution was then transferred to a 5 mm U-Thin 
NMR tube. 1D proton NMR spectra were collected at 8 scans. 2D cosy scans were collected at 2 
scans, 256 increments. 
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3.7. Infrared Spectroscopy 
 Infrared spectra were obtained using a Perkin-Elmer Spectrum Two IR Spectrometer 
with attached UATR in the range of 500-4000 nm. Briefly a small amount of lyophilized sample 
was placed on the UATR and the appropriate pressure was applied. 
3.8. LogD Studies 
 To determine the extinction coefficients the radioactive metal (99mTc, 188Re) complexes 
dried via high vacuum system following synthesis. The product was reconstituted in PBS and 
placed into a micro centrifuge tube with an equal amount of 1 octanol. The samples were 
vortexed followed by centrifugation at 10,000 rpm for 5 minutes. 
3.9. SPECT Imaging 
 Pretargeting SPECT imaging experiments were conducted on a NanoSPECT/CT Plus In 
Vivo Animal Imager. Athymic nude female mice 6-8 weeks old bearing subcutaneous SW1222 
xenografts (right shoulder, 100 -150 mm3, 14-21 days post-inoculation) were administered 125 
µg. A33-TCO (in 250 µL PBS) via tail vein injection. Prior to imaging mice were anesthetized by 
inhalation of a 2% isofluorane: oxygen gas mixture and placed on a scanner bed. SPECT data 
was obtained for each mouse (5 mice per time point) at 1 hour, 4 hour and 8 hour post 
injection. Following imaging mice were sacrificed. The following tissues were collected, blood, 
tumor, heart, lungs, liver, spleen, stomach, small intestines, large intestines, kidneys, muscle, 
bone, skin, thyroid, and gall bladder. The tissues were then counted on a Perkin Elmer 
Automatic Wizard γ counter and the %ID/g and were calculated and reported. 
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3.10. Biodistribution Studies 
 The 99mTc and 188Re labelled KYCAR tetrazine complexes were evaluated for their 
biological distribution in healthy athymic nude female mice 6-8 weeks old. About 100 to 200 µCi 
(3.7 X103 7.4 X103 kBq) of the radiolabeled complex was injected intravenously into the mice via 
the tail vein. Mice were sacrificed 30 minutes, 1 hour, 2 hour, and 4 hour post injection; 5 mice 
per time point.  The following tissues were collected, blood, heart, lungs, liver, spleen, stomach, 
small intestines, large intestines, kidneys, muscle, bone, skin, thyroid, and gall bladder. The 
tissues were then counted on a Perkin Elmer Automatic Wizard γ counter and the %ID/g were 
calculated and reported.  
 Blood half-life studies were completed by injecting 100 µCi to 200 µCi (3.7 X103 - 7.4 
X103 kBq) of the radiolabeled complex into in healthy athymic nude female mice 6-8 weeks old, 
intravenously via the tail vein. Mice were sacrificed 5 minutes, 15 minutes, 30 minutes, and 1 
hour post injection; 4 mice per time point. Terminal blood draws were collected via cardiac 
puncture. The tissues were then counted on a Perkin Elmer Automatic Wizard γ-counter and 
the percent injected dose per gram (%ID/g) were calculated and reported.  
 
3.11. Results and Discussion 
3.11.1. Synthesis of 99mTcO-KYCAR, 188ReO-KYCAR, and ReO-KYCAR tetrazines 
 The reaction of ReO-KYCAR with either short-tetrazine NHS ester or PEG5-tetrazine in 
the presence of DIEA results in on major product. The amine found on the side chain of KYCAR’s 
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lysine is deprotonated by the DIEA producing a NH2
-. This nucleophile then attacks the carbonyl 
of the tetrazine resulting in the conjugation of the tetrazine to the ligand and NHS ester as a 
byproduct (Figure 45). It is theoretically possible that the conjugation could occur at the 
guanidium group of the arginine, however it is highly unlikely due to steric hindrances.   
 
 
 
Figure 45. Lysine-tetrazine Reaction Mechanism 
 
 
3.11.2. Reversed phase HPLC Analysis and Mass Spectroscopy 
 Following the synthesis of ReO-KYCAR with Sh-tetrazine the reaction mixture was 
purified via reversed phased HPLC (Figure 46). The major fraction was collected and lyophilized. 
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Figure 46. HPLC of ReO-KYCAR-Sh-Tz showing one major peak. 
 
 
The lyophilized sample was then submitted for mass spectral analysis where it was determined 
that the collected product carried the appropriate molecular ion [M + H]+ peak at m/z 1038 
(Figure 47) which corresponds to the exact mass of 1037.30 g/mol. 
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Figure 47. Mass Spectroscopy of ReO-KYCAR-Sh-Tz molecular ion [M + H]
+
 peak at m/z 1038 which corresponds to 
an exact mass of 1037.30 g/mol. 
 
 
Similarly, the ReO-KYCAR-PEG5-Tz was purified viz HPLC (Figure 48) and the lyophilized product 
was analyzed after mass spectral submission (Figure 49). The mass spectroscopy also shows a 
pure sample with the appropriate molecular ion [M + H]+ peak at m/z 1329, corresponding to an 
exact mass of 1328.47 g/mol 
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Figure 48. HPLC of ReO-KYCAR-PEG5-Tz showing one major peak 
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Figure 49. Mass Spectroscopy of ReO-KYCAR-PEG5-Tz molecular ion [M + H]
+
 peak at m/z 1329 which corresponds 
to an exact mass of 1328.47 g/mol. 
 
 
3.11.2.1. Coelution studies  
 To correlate the macroscopic Re product with the trace level 99mTc and 188Re products, 
coelutions of the two materials were HPLC analyzed. Due to the increased stability of the 99mTc 
products they were chosen to perform coelution test. The ReO-KYCAR-Sh-Tz/99mTcO-KYCAR-Sh-
Tz coelution (Figure 59) shows the macroscopic rhenium product eluting between 16 and 18.5 
minutes, and the tracer technetium product eluting between 16.5 and 19 minutes.  
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Figure 50. Coelution of ReO-KYCAR-Sh-Tz and 
99m
TcO-KYCAR-Sh-Tz 
 
 
 ReO-KYCAR-PEG5-Tz was then coeluted with 
99mTcO-KYCAR-PEG5-Tz (Figure 51). 
Comparable to the Sh-Tz system the macroscopic rhenium elutes between 18 and 24 minutes 
and the technetium product elutes between 19 and 24 minutes. Here it is observed that the 
products elute with multiple peaks. This is due to the interaction of the bulky PEG5 complex 
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with the column. This phenomenon is less observed with the cold rhenium due to its 
macroscopic nature.  
 
 
 
Figure 51. Coelution of ReO-KYCAR-PEG5-Tz and 
99m
TcO-KYCAR-PEG5-Tz 
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3.11.3. Infrared Spectroscopy 
 After conjugation with the Sh-Tz the infrared spectra of ReO-KYCAR-Sh-Tz (Figure 52) 
retains the Re=O stretching frequency around 1000 cm -1. However, it is slightly obscured by the 
stretching frequencies of the compound’s secondary amide C=O amine III band. Overall the 
indication of a successful conjugation lies in the change in intensities in the various functional 
groups. Most noticeable is the phenol, carboxylic acid O-H and amine N-H stretching 
frequencies, 2800 cm-1- 3500 cm-1, which exhibits a medium frequency. This is also observed at 
1665 cm-1 and 1655 cm-1, a very strong intensity, which correspond to the increase in the 
amount of C=N and C=C bonds within the compound. 
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Figure 52. Infrared Spectra of ReO-KYCAR-Sh-Tz 
 
 
 The infrared spectra of ReO-KYCAR-PEG5-Tz exhibit a very similar fingerprint to that of 
ReO-KYCAR-Sh-Tz in the observation of the intensities of the frequencies. However, ReO-
KYCAR-PEG5-Tz can be distinguished by the C-H fingerprint at a stretching frequency of 2880 
cm-1 – 2930 cm-1 (Figure 53) 
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Figure 53. Infrared Spectra of ReO-KYCAR-PEG5-Tz 
 
 
3.11.4. Biology 
 To obtain a baseline of distribution of the newly conjugated complex in vivo the 
complexes we injected in PBS into healthy athymic nude female mice. The biological 
distribution of 99mTcO-KYCAR-Sh-Tz is tabulated in table 15 and shown in Figure 54.  
 
 
112 
 
 
 
Table 15. Biodistribution of 
99m
TcO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows that the activity travels 
through the gastrointestinal track. 
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Figure 54. Biodistribution of 
99m
TcO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows that the activity travels 
through the gastrointestinal track. 
 
 
 Thirty minutes post injection the large majority of the uptake is found in the small 
intestines (25.45 ± 16.06 %ID/g). There is a noticeable decrease in small intestine uptake (11.13 
± 12.88 %ID/g) after one hour, followed by eventual complete depletion. Simultaneously as 
depletion occurred in the small intestines uptake increased in the large intestines (from 0.27 ± 
0.21 %ID/g at 1 hour to 37.05 ± 15.15 %ID/g at 2 hours). The activity found in the large 
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intestines continues to increase at 4 hours post injection (64.43 ± 30.15 %ID/g). These observed 
trends matched the in vitro studies showing the lipophilicity of the complex (logD= -0.975). 
There is a slight uptake and depletion found in the thyroid, which could correlate to some 
decomposition of the complex to 99mTcO4
-. Overall the complex shows favorable stability in vivo 
showing no inexplicable uptake. 
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Table 16. Biodistribution of 
188
ReO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows that the activity travels 
through the gastrointestinal track. Also shows some decomposition to 
188
ReO4
-
 through stomach and thyroid 
accumulation. 
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Figure 55. Biodistribution of 
188
ReO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows that the activity travels 
through the gastrointestinal track. Also shows some decomposition to 
188
ReO4
-
 through stomach and thyroid 
accumulation. 
 
 
 The biological distribution of 188ReO-KYCAR-Sh-Tz is tabulated in table 16 and shown in 
Figure 55. The 188ReO-KYCAR-Sh-Tz complex behaves similarly to the technetium complex. 
There is very little uptake seen in most organs which mostly indicates rapid excretion. In vitro 
studies show that the compound is slightly lipophilic (logD= -0.967). This is observed by the 
uptake into the small intestines 30 minutes (54.52 ± 33.31 %ID/g), and 1 hour (45.06 ± 39.93 
%ID/g) post injection. Followed by uptake in the large intestines at 2 hours (60.73 ± 27.32 
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%ID/g) and 4 hours post injection (82.23 ± 33.28 %ID/g). Unlike the technetium complex there 
is a slight stomach uptake and retention of the rhenium complex, which remains constant 
(16.36 ± 10.24 %ID/g at 30 minutes to 15.12 ± 8.97 %ID/g at 4 hours). The uptake and retention 
in the stomach is indicative of absorption of free 188ReO4
-. Another observation of 
decomposition within the compound is the uptake in the thyroid, (87.43 ± 18.56 %ID/g and 30 
minutes to 154.53 ± 103.63 %ID/g at 4 hours).  
 The biological distribution of 99mTcO-KYCAR-PEG5-Tz is tabulated in table 17 and shown 
in Figure 56. Compared to the biological distribution of the technetium complex with Sh-Tz the 
uptake in the organs as a whole is increased. Despite the increased hydrophilicity of this 
compound (logD= -1.83) the excretion route remains through the gastrointestinal tract. 
Stomach uptake and retention remains (56.17 ± 11.92 %ID/g at 30 minutes to 54.13 ± 38.51 
%ID/g at 2 hours). Followed by a shift to the large intestines at 4 hours (70.23 ± 9.90 %ID/g). An 
increased uptake in seen in the thyroid (37.46 ± 28.31 %ID/g at 30 minutes to 387.09 ± 80.29 
%ID/g at 4 hours) indicating possible decomposition to pertechnetate. 
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Table 17. Biodistribution of 
99m
TcO-KYCAR- PEG5-Tz. The results are reported in %ID/g. Shows that the activity 
travels through the gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 over time through slow 
thyroid accumulation. 
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Figure 56. Biodistribution of 
99m
TcO-KYCAR- PEG5-Tz. The results are reported in %ID/g. Shows that the activity 
travels through the gastrointestinal track. Also shows some decomposition to 
99m
TcO4
-
 over time through slow 
thyroid accumulation. 
 
 
 The biological distribution of 188ReO-KYCAR-PEG5-Tz is tabulated in table 18 and shown 
in Figure 57. Excretion through the gastrointestinal tract is observed with the 188ReO-KYCAR-
PEG5-Tz complex despite the hydrophilic nature (logD= -1.69). Uptake begins in the small 
intestines (31.26 ± 23.02 %ID/g at 30 minutes to 42.47 ± 43.64 %ID/g at 1 hour). This is followed 
by a shift into the large intestines (52.47 ± 26.99 %ID/g at 2 hours to 65.09 ± 34.49 %ID/g at 4 
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hours). Decomposition is observed in the thyroid (124.63 ± 27.34 %ID/g at 30 minutes to 161.72 
± 75.86 %ID/g at 4 hours) and also in the stomach (10.84 ± 4.26 %ID/g at 30 minutes to 8.44 ± 
6.18 at 4 hours). However, there is insignificant uptake found in all other organs. 
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Table 18. Biodistribution of 
188
ReO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Shows that the activity 
travels through the gastrointestinal track. Also shows some decomposition to 
188
ReO4
-
 through stomach and 
thyroid accumulation. 
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Figure 57. Biodistribution of 
188
ReO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Shows that the activity 
travels through the gastrointestinal track. Also shows some decomposition to 
188
ReO4
-
 through stomach and 
thyroid accumulation. 
 
 
 Throughout all biological distributions in healthy mice the clearance within each system 
seems to be rapid which show promise for reducing dose to non-target organs. Regardless of 
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the change in the partition coefficients the route of excretion appears to remain through the 
gastrointestinal tract. There is slight decomposition of the complexes found throughout each 
system, though it is more prevalent in the 188Re systems.  
 To observe the rate at which 99TcO-KYCAR-PEG5-Tz were removed from the 
bloodstream, blood half-life studies were completed. Using a two phase decay, via Prism, the 
two components of the blood half-life were obtained. The fast component was determined to 
be 0.024 minutes which means the majority of the compound is removed from the blood in <30 
seconds. The slow component was determined to be 4.597 minutes which show that the 
remainder of the construct that is in the blood stream circulates for about 5 additional minutes. 
3.11.4.1. Biological Studies in Tumored Mice 
 In order to observe the stability of 99mTcO-KYCAR-PEG5-Tz-A33-TCO and the 
effectiveness of the entire moiety through tumor uptake, the 99mTcO-KYCAR-PEG5-Tz was 
clicked to A33-TCO ex vivo prior to injection into SW1222 xenografted mice. This is called “pre-
clicked”, here the antibody drives the biodistribution. The biological distribution of the pre-
clicked 99mTcO-KYCAR-PEG5-Tz-A33-TCO is tabulated in table 19 and shown in Figure 58. 
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Table 19. Pre-clicked Biodistribution of 
99m
TcO-KYCAR- PEG5-Tz-A33-TCO. The results are reported in %ID/g. Shows 
retention of activity in the blood due to long circulation time. Also shows significant tumor uptake. 
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Figure 58. Pre-clicked Biodistribution of 
99m
TcO-KYCAR- PEG5-Tz-A33-TCO. The results are reported in %ID/g. Shows 
retention of activity in the blood due to long circulation time. Also shows significant tumor uptake. 
 
 
 In the pre-clicked biodistribution experiment, the antibody drives the biodistribution 
and this experiment can inform about the stability of the 99mTc construct. The first noticeable 
but expected observation is the retention of the moiety in the blood (32.95 ± 6.08 %ID/g at 1 
hour to 38.62 ± 12.03 %ID/g at 8 hours). This is attributed to the long circulation time of the 
antibody which typically takes up to 24 hours to completely localize. In fact, the presence of 
increased antibody in the blood is shown as increased uptake throughout all organs. There is a 
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dramatic decrease in uptake within the gastrointestinal tract. Retention in the small intestine 
decreases throughout the time points (from 7.11 ± 3.68 %ID/g at 1 hour to 4.34 ± 1.15 %ID/g at 
8 hours). There is a slight increase in uptake in the large intestine across the time points (0.80 ± 
0.26 %ID/g at 1 hour to 10.82± 3.64 %ID/g at 8 hours). These values seem negligible when 
compared to 99mTcO-KYCAR-PEG5-Tz in healthy mice. There is significant tumor uptake present 
which is most notable. At 1 hour post injection, there is 9.26 ± 6.25 %ID/g and the uptake 
increases to 32.76 ± 4.21 %ID/g at 4 hours and 31.05 ± 9.78 %ID/g at 8 hours. The increase in 
the thyroid suggests decomposition of the Tc complex to form pertechnetate. However, the 
biodistribution results suggest that the 99mTcO-KYCAR-PEG5-Tz-A33-TCO construct is reasonably 
stable in vivo for moving forward with pretargeting experiments. SPECT imaging of the 99mTcO-
KYCAR-PEG5-Tz-A33-TCO in SW1222 xenografted mice were carried out simultaneously with 
biodistribution studies (Figure 59). As expected 1 hour after injection there is a large amount of 
activity remaining in the blood pool. This continues for each subsequent time point. The 
bladder, which is not observed in the biodistribution, obtains the most uptake at hour 1, but is 
completely undetected for other time points. At 4 hours post injection, the gallbladder is where 
the majority of uptake is retained. The tumor shows uptake throughout all time points; 
however it is difficult to distinguish from the blood pool. 
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Figure 59. SPECT Images of pre-clicked 
99m
TcO-KYCAR-PEG5-Tz-A33-TCO. A large amount of activity is found in the 
blood pool through all time points. However, shows significant tumor uptake by 8 hours. The tumor is marked by 
the white arrow. 
 
 
 The pre-clicked imaging demonstrated that the 99mTc construct is reasonably stable in 
vivo. Moving forward pretargeting experiments were evaluated for each system. The biological 
distribution of 99mTcO-KYCAR-Sh-Tz pretargeted with A33-TCO is tabulated in table 20 and 
shown in Figure 60.  
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Table 20. Pretargeted Biodistribution of 
99m
TcO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows an unusual 
high accumulation in the muscle. There is some decomposition 
99m
TcO4
-
 accumulating over time in the thyroid, a 
minimal tumor uptake. 
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Figure 60. Pretargeted Biodistribution of 
99m
TcO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows an unusual 
high accumulation in the muscle. There is some decomposition 
99m
TcO4
-
 accumulating over time in the thyroid, a 
minimal tumor uptake. 
 
 
The biological distribution shows minimal uptake in most organs. There is an unusually high 
uptake found in the muscle that shows an upward trend with each time point. At 1 hour post 
injection, the muscle showed 4.46 ± 6.02 %ID/g, at 4 hours it showed 8.58 ± 5.30 %ID/g, and at 
8 hours 17.05 ± 29.45 %ID/g. This result is surprising since there was little uptake in the muscle 
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shown in biological distribution in healthy mice. The complex is not retained in small intestines; 
however, some uptake is seen at 4 and 8 hour post injection in the large intestine (30.81 ± 
18.47 %ID/g and 12.58 ± 21.05 %ID/g respectively). The thyroid shows a significant upward 
trend through each time point (22.42 ± 6.81 %ID/g at 1 hour and 71.85 ± 102.00 %ID/g at 8 
hours) This could be indicative of decomposition to 99mTcO4
-. The tumor uptake is minimal; at 1 
hour uptake is 1.26 ± 0.20 %ID/g, 4 hour it is 5.14 ± 20.6 %ID/g, and 8 hour is 0.96 ± 0.62 %ID/g.  
 Simultaneous SPECT images were also collected, and immediately the uptake in the 
blood is considerably lower than in the pre-clicked experiments, lowering the background 
(Figure 61). At 1 hour post injection, the small intestines and bladder exhibit the major uptake 
in the images. Also, the gallbladder shows accumulation which is seen in the biodistribution at 
early time points. Throughout the remaining timepoints the uptake moves through the large 
intestine and remains in the gallbladder. Tumor uptake at 1 and 4 hours post injection is 
observed and is distinctive, however by hour 8 the activity found in the tumor has decreased.  
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Figure 61. Pretargeted SPECT Images of 
99m
TcO-KYCAR-Sh-Tz. Shows high accumulation in the gallbladder in early 
time points. There is a large amount of gut uptake. Tumor uptake at 1 and 4 hours post injection is observed and 
distinctive. The tumor is marked by the white arrow. 
 
 
 The biological distribution of 188ReO-KYCAR-Sh-Tz pretargeted with A33-TCO is tabulated 
in table 21 and shown in Figure 62. 
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Table 21. Pretargeted Biodistribution of 
188
ReO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows an unusual 
high accumulation in the muscle. There is some decomposition 
188
ReO4
-
 accumulating in the thyroid and stomach, 
Minimal tumor uptake. 
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Figure 62. Pretargeted Biodistribution of 
188
ReO-KYCAR-Sh-Tz. The results are reported in %ID/g. Shows an unusual 
high accumulation in the muscle. There is some decomposition 
188
ReO4
-
 accumulating in the thyroid and stomach, 
Minimal tumor uptake. 
 
 
Stomach uptake is apparent, although a reduction in uptake is seen at each time point (12.15 ± 
2.32 %ID/g at 1 hour and 4.35 ± 5.94 %ID/g at 8 hour). There is also uptake and depletion found 
in the thyroid (154.10 ± 29.54 %ID/g at 1 hour and 68.14 ± 47.77 %ID/g). Accumulation in both 
organs suggests decomposition to 188ReO4
-. Movement through the gastrointestinal track is 
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observed, and is likely due to circulation of unclicked complex. Small intestines show uptake at 
1 hour (22.31 ± 24.45 %ID/g) and the large intestines show uptake at 4 and 8 hours (43.13 ± 
7.99 %ID/g and 18.57 ± 10.88 %ID/g, respectively). There is minimal uptake found in the tumor 
(1.46 ± 0.13 %ID/g at 1 hour and 1.85 ± 0.31 %ID/g at 8 hours). 
 SPECT images of the 188ReO-KYCAR-Sh-Tz complex were also obtained (Figure 63). At 1 
hour post injection the gallbladder, small intestines and bladder all show uptake. Gut uptake 
remains throughout all timepoints. Tumor uptake is not observed, low tumor uptake and low 
gamma emission could be the cause. 
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Figure 63. Pretargeted SPECT Images of 
188
ReO-KYCAR-Sh-Tz. Shows high accumulation in the gallbladder, small 
intestines and bladder. Tumor uptake is not observed. Tumor is marked by the white arrow. 
 
 
 The biological distribution of 99mTcO-KYCAR-PEG5-Tz pretargeted with A33-TCO is 
tabulated in table 22 and shown in Figure 64. 
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Table 22. Pretargeted Biodistribution of 
99m
TcO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Shows possible 
unclicked 
99m
TcO-KYCAR-PEG5-Tz in the gastrointestinal track. Shows slow accumulation at the tumor site. 
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Figure 64. Pretargeted Biodistribution of 
99m
TcO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Possible 
unclicked 
99m
TcO-KYCAR-PEG5-Tz is found in the gastrointestinal track. These data show slow accumulation at the 
tumor site. 
 
 
 
Uptake is found at higher elevation for all organs in comparison to the previous systems. There 
is a rapid accumulation and depletion observed in the blood (19.81 ± 4.45 %ID/g at 1 hour and 
14.64 ± 2.02 %ID/g at 8 hours). This quick accumulation and depletion is also found in the lungs 
(14.20 ± 6.33 %ID/g at 1 hour and 7.47 ± 1.33 %ID/g at 8 hours) and liver (10.89 ± 2.83 %ID/g at 
1 hour and 5.41 ± 0.62 %ID/g at 8 hours). Unclicked 99mTcO-KYCAR-PEG5-Tz complex is likely 
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observed in the gastrointestinal track. The small intestines show uptake at 1 hour (125.56 ± 
159.93 %ID/g), and the accumulation travel to the large intestines (201.59 ± 94.52 %ID/g at 4 
hours and 191.59 ± 187.42 %ID/g). Most notably there is a slow accumulation at the tumor site. 
At 1 hour post injection (10.31 ± 2.24 %ID/g), 4 hour (13.42 ± 4.05 %ID/g) and 8 hour (20.04 ± 
3.26 %ID/g). 
 Simultaneously SPECT images were collected (Figure 65). As previous studies show most 
accumulation is seen in the gallbladder, small intestines and bladder at 1 hour. Gut uptake 
remains most prevalent throughout the timepoints. Uptake at the tumor site is rapid and is 
retained throughout the time points. Moreover, tumor accumulation is discernible throughout. 
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Figure 65. Pretargeted SPECT Images 
99m
TcO-KYCAR-PEG5-Tz. Shows high accumulation in the gallbladder, small 
intestines and bladder. Tumor uptake is observed and discernable throughout the experiment. The tumor is 
marked by the white arrow. 
 
 
 The biological distribution of 188ReO-KYCAR-PEG5-Tz pretargeted with A33-TCO is 
tabulated in table 23 and shown in Figure 66. 
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Table 23. Pretargeted Biodistribution of 
188
ReO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Shows high 
accumulation in the gastrointestinal track. There is decomposition 
188
ReO4
-
 accumulating in the thyroid and 
stomach, Minimal tumor uptake. 
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Figure 66. Pretargeted Biodistribution of 
188
ReO-KYCAR-PEG5-Tz. The results are reported in %ID/g. Shows high 
accumulation in the gastrointestinal track. There is decomposition 
188
ReO4
-
 accumulating in the thyroid and 
stomach, Minimal tumor uptake. 
 
The biological distribution shows a slight accumulation and depletion in the blood (2.33 ± 0.30 
%ID/g at 1 hour and 1.74 ± 0.23 %ID/g at 8 hours). Uptake in the stomach (8.09 ± 5.00 %ID/g at 
1 hour , 10.40 ± 6.51 %ID/g at 4 hours and 5.14 ± 2.62 %ID/g at 8 hours) shows decomposition. 
Uptake and depletion in the thyroid (124.55 ± 50.26 %ID/g at 1 hour, 136.91 ± 86.29 %ID/g at 4 
hours, and 67.45 ± 30.06 %ID/g at 8 hours) also indicated decomposition. Intact unclicked 
188ReO-KYCAR-PEG5-Tz complex travels through the gastrointestinal track. The small intestines 
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show uptake and depletion (30.63 ± 24.74 %ID/g at 1 hour, 14.56 ± 29.74 %ID/g at 4 hours and 
0.50 ± 0.25 %ID/g). Slow accumulation is observed in the large intestines (0.32 ± 0.21 %ID/g at 1 
hour, 23.50 ± 36.68 %ID/g at 4hours, and 28.23 ± 14.23 %ID/g at 8 hours). Tumor accumulation 
is minimal and steady (1.06 ± 0.06 %ID/g at 1 hour, 1.50 ± 0.51 %ID/g at 4 hours, and 1.64 ± 
0.21 %ID/g at 8 hours. 
3.12. Conclusion 
 99mTc,188Re and Re peptides were successfully conjugated to two different tetrazine 
moieties. The conjugations were purified via HPLC and cold complexes were first confirmed by 
mass spectroscopy. IR data further concludes conjugation by the changes in the intensities of 
stretches. Because these constructs are novel the characterization of them creates a baseline 
for further optimization.  
 The 99mTc,188Re Sh-tetrazine complexes in healthy mice both are excreted through the 
gastrointestinal track. In both systems, high initial uptake is observed in the small intestine 
which shifts to the large intestines 2 hour post injection. This is somewhat expected due to the 
lipophilicity of the complexes. There is little decomposition shown in the technetium 
complexes, while the rhenium complex shows considerable thyroid accumulation.  
 The 99mTc,188Re PEG5-tetrazine complexes in healthy mice are unaffected by increase of 
hydrophilic components and the route of excretion remains through the gastrointestinal track. 
The technetium complexes show decomposition, observed as accumulation in the thyroid than 
the 99mTcO-KYCAR-Sh-Tz complex. Similarly, the rhenium PEG5-tetrazine complex also 
decomposes in vivo, and shows uptake in the stomach and thyroid.  
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 The pre-clicked moiety,99mTcO-KYCAR-PEG5-Tz-A33-TCO, showed less accumulation 
through the gastrointestinal track, though high uptake in the blood pool. Favorable tumor 
uptake is achieved; however, tumor uptake competes with uptake in the blood pool. 
 Pretargeting experiments overall show less than desirable tumor accumulations. In the 
Sh-Tz systems the technetium complexes showed an unusual accumulation in the muscle. 
These complexes also exhibited slight decomposition and excretion through the gut, however 
SPECT images show discernible tumor uptake. The rhenium Sh-Tz complexes behave similarly to 
the technetium complex. The biodistribution data shows slight tumor uptake, though it is not 
visible through SPECT imaging.  
 The PEG5-Tz complexes both show decomposition and gut excretion despite their 
hydrophilic nature. The 99mTcO-KYCAR-PEG5-Tz complex exhibited the best tumor accumulation 
of the 4 complexes. Despite the considerable gut uptake other non-target organs are relatively 
low thus showing distinct tumor uptake in SPECT images. 
 Comparing the pre-clicked experiment to the pretargeting experiments it is 
hypothesized that the decrease tumor uptake is due to the rapid clearance of the complex from 
the blood. The small size of the radioligand possibly only allows one pass through the tumor site 
for the click reaction to occur. Another possibility is that the A33-TCO is circulation in the blood 
thus preventing click reaction to occur at the tumor site. It is important to note that in each 
system, in healthy and SW1222 xenografted mice there is appreciable uptake in the gall 
bladder. It hypothesized that accumulation to the gallbladder is influenced by the C-terminus of 
the pentapeptide.  
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4. Summary 
 Complexes with 99mTc and 188Re and a pentapeptide (KYCAR) have been synthesized, and 
characterized by the macroscopic non-radioactive Re. The non-radioactive rhenium-peptide 
shows that there are two isomeric species that elute within minutes of each other. IR data 
further concludes that the two isolated species are diasteromers due to the similar stretches 
and frequencies. Proton NMR data first confirms the chelation between Re and KYCAR by 
showing the deprotonation of the amide nitrogens on the tyrosine and cysteine residues. The 
data also confirms this through the observation of the shifts in the β-protons on both the lysine 
side chain and the cysteine side chain. The proton NMR also assists in the assignment of the 
diastereomers. Purified peak 2 (syn) has chemical shifts downfield from the fre ligand as well as 
the first peak which correlates to the desheilding effect imposed by the position of the Re-oxo 
core. Circular dichroism gives solid information on the diastereomers. This data shows that 
peak 1 (anti) follows the trend of having a large positive cotton effect about the region that 
correlates to the oxygen rhenium charge transfer transition. It also shows that peak 2 (syn) 
follows the trend of having a negative Cotton effect about the same region. Through the 
crystallization of ReO-KYC information about the structure about the chelating region was 
obtained. It was determined that the crystal in its syn confirmation correlates to peak in HPLC 
analyses. This concludes that ReO-KYCAR peak 2 is also in the syn confirmation. 
 The fully characterized ReO-KYCAR was successfully coeluted with the tracer level 
99mTcO-KYCAR and 188ReO-KYCAR to confirm that the complexes were chemically similar. In vitro 
both complexes are relatively stable in biological conditions up to 2 hours. In vivo 99mTcO-KYCAR 
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shows high uptake in the liver small intestines, and large intestines up to 4 hours post injection. 
The technetium compound is excreted via the hepatobiliary system, remains relatively stable. 
The 188ReO-KYCAR show very similar organ uptake to its technetium congener. The rhenium 
complex is less stable, decomposing to perrhenate, accumulating in the stomach and thyroid. 
 Novel conjugations between non-radioactive ReO-KYCAR and tetrazine (sh-Tz and PEG5-
Tz) moieties were successful. These conjugations were purified, characterized, and confirmed 
by reverse phase HPLC, mass spectral analysis, and IR. The characterized complexes were then 
used to confirm the syntheses of the 99mTc and 188Re complexes.  
 Biologically in healthy mice the 99mTc and 188Re Sh-tetrazine complexes are excreted 
through the gastrointestinal track. There is little decomposition shown in the technetium 
complex, while the rhenium complex shows thyroid accumulation. The 99mTc and 188Re PEG5-
tetrazine complexes are also excreted through the gastrointestinal track despite the increase of 
hydrophilic components. Both complexes show decomposition; Tc shows accumulation in the 
thyroid and Re shows accumulation in the stomach and thyroid.  
 The pre-clicked moiety 99mTcO-KYCAR-PEG5-Tz-A33-TCO shows favorable tumor uptake, 
though tumor uptake competes with uptake in the blood pool. Pretargeting experiments with 
99mTcO-KYCAR-Sh-Tz show slight decomposition and excretion through the gut, however SPECT 
images show discernable tumor uptake. The complex 188ReO-KYCAR-Sh-Tz behaves similarly to 
the technetium complex. biodistribution data show tumor uptake, despite being invisible 
through SPECT imaging. The 188ReO-KYCAR-PEG5-Tz complex shows minimal tumor uptake, and 
has increased decomposition to 188ReO4
-. The 99mTCO-KYCAR-PEG5-Tz complex exhibited the 
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best tumor accumulation of the 4 pretargeting complexes. Despite the considerable gut uptake 
dose to other non-target organs is low thus showing distinct tumor uptake in SPECT images. 
 These constructs show promise for in vivo applications. The characterization of the 
nonradioactive rhenium complexes creates a baseline library for the investigation of similar 
constructs. These constructs could be optimized further to enhance the biological results. Some 
future experiments for the optimization of these complexes are summarized in the next 
chapter. 
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5. Future Work 
 Investigations of the effects of altering the order or exchanging the amino acids within 
the peptide could produce a more favorable chelator and result in better in vivo distribution. 
Exchanging the C-terminus on the arginine for an amine could prevent uptake in the 
gallbladder. Crystallization of the anti ReO-KYC should be completed to fully understand the 
diastereomers of the ReO-KYCAR complexes. 
 To optimize the radiolabeling process the peptide could be conjugated to the tetrazine 
prior to radiolabeling. This could reduce the decomposition that occurs by radiolabeling the 
entire chelator in one step. 
 Conjugation to other tetrazines should be tested, which could increase in vivo click at 
the tumor site. Bulkier tetrazines will increase the molecular weight and could assist in slowing 
the blood clearance, thus facilitating occurrence of click reactions at the tumor site.   
 In pretargeting experiments the use of a clearing agent should be investigating to 
observe whether dose to non-target organs is decreased. Injecting with a clearing agent after 
the injection of the antibody will assist in removing residual antibody circulating through the 
body. This extra step can increase tumor uptake and decrease dose to non-tumor organs. 
 To enhance the stability of 188Re-peptide conjugation a radioprotectant that is inert to 
the components of the chelator should be used. The emitted β particle causes damage to the 
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catalysts and other compounds in the reaction mixture. The radioprotectant can absorb the β 
particle reducing the radiolytic damage.  
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